[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 360
6. Simmons HM, Ruis BL, Kapoor M, Hudacek AW, Conklin KF: Identification of NOM1, a nucleolar, eIF4A binding protein encoded within the chromosome 7q36 breakpoint region targeted in cases of pediatric acute myeloid leukemia. Gene; 2005 Feb 28;347(1):137-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of NOM1, a nucleolar, eIF4A binding protein encoded within the chromosome 7q36 breakpoint region targeted in cases of pediatric acute myeloid leukemia.
  • In this report, we describe the characterization of a novel MIF4G/MA3 family member called NOM1 (nucleolar protein with MIF4G domain 1) that was identified at the chromosome 7q36 breakpoint involved in 7;12 translocations associated with certain acute leukemias of childhood.
  • [MeSH-major] Chromosomes, Human, Pair 7 / genetics. Eukaryotic Initiation Factor-4A / metabolism. Exons / genetics. Leukemia, Myeloid, Acute / genetics. Nuclear Proteins / genetics. RNA-Binding Proteins / genetics


7. Anak S, Saribeyoglu ET, Bilgen H, Unuvar A, Karakas Z, Devecioglu O, Agaoglu L, Gedikoglu G: Allogeneic versus autologous versus peripheral stem cell transplantation in CR1 pediatric AML patients: a single center experience. Pediatr Blood Cancer; 2005 Jun 15;44(7):654-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic versus autologous versus peripheral stem cell transplantation in CR1 pediatric AML patients: a single center experience.
  • BACKGROUND: Treatment of childhood acute myelocytic leukemia (AML) in first remission, is still evolving.
  • PROCEDURE: Out of 81 pediatric patients with AML in first CR, 67 were biologically randomized for allogeneic (n = 31), autologous (n = 20), or peripheral stem cell transplant (n = 16) after completing consolidation treatment, with the remaining (n = 11) dropping out or receiving chemotherapy.
  • CONCLUSION: In pediatric AML patients without a donor, autologous BMT or autologous PBSCT appears to be an effective treatment option with low transplant related mortality especially in less privileged countries where the chemotherapy only results are still low.
  • [MeSH-major] Bone Marrow Transplantation. Leukemia, Myeloid / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15700262.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Landers MC, Malempati S, Tilford D, Gatter K, White C, Schroeder TL: Spontaneous regression of aleukemia congenital leukemia cutis. Pediatr Dermatol; 2005 Jan-Feb;22(1):26-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous regression of aleukemia congenital leukemia cutis.
  • A full-term 2-week-old boy was referred to the pediatric dermatology clinic with numerous blue to violaceous nodules present since birth.
  • A skin biopsy specimen showed an atypical cellular infiltrate suspicious for leukemia or lymphoma.
  • A bone marrow biopsy specimen demonstrated acute myelogenous leukemia (M4 subtype).
  • Following consultation with pediatric oncology and the recognition of the potential for spontaneous regression, chemotherapy for the infant's condition was not recommended.
  • We report this instance of aleukemic congenital leukemia with spontaneous regression of leukemia cutis without therapeutic intervention.
  • [MeSH-major] Leukemia / pathology. Leukemia, Myeloid / pathology
  • [MeSH-minor] Acute Disease. Humans. Infant, Newborn. Male. Remission, Spontaneous

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660893.001).
  • [ISSN] 0736-8046
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Radhi M, Meshinchi S, Gamis A: Prognostic factors in pediatric acute myeloid leukemia. Curr Hematol Malig Rep; 2010 Oct;5(4):200-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in pediatric acute myeloid leukemia.
  • Acute myeloid leukemia (AML), a heterogeneous group of diseases with variable responses to the same therapy, comprises nearly a quarter of childhood acute leukemias.
  • Although historically very few prognostic markers have been incorporated into therapeutic decision making in AML, recent advances in technology have enabled identification of numerous factors associated with disease outcome.
  • This review provides a detailed analysis of most clinically relevant factors associated with disease outcome in childhood AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis
  • [MeSH-minor] Age Factors. Biomarkers, Tumor. Body Mass Index. Child. Cytogenetics. Humans. Polymorphism, Genetic. Prognosis. Risk Factors. Sex Factors

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Jul 1;108(1):74-80 [16537811.001]
  • [Cites] Curr Opin Hematol. 2005 Jan;12(1):62-7 [15604893.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3904-11 [16921041.001]
  • [Cites] Blood. 2009 May 7;113(19):4505-11 [19221039.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2527-37 [17965322.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5705-17 [16110030.001]
  • [Cites] Leukemia. 2002 May;16(5):776-84 [11986937.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S108-12 [15124698.001]
  • [Cites] Blood. 2006 May 1;107(9):3463-8 [16384925.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1279-87 [11230469.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] Best Pract Res Clin Haematol. 2008 Dec;21(4):621-8 [19041601.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1044-53 [18000167.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4641-7 [17299091.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1806-9 [16291592.001]
  • [Cites] Blood. 1985 Feb;65(2):298-304 [3881140.001]
  • [Cites] Cancer. 2008 Jan 15;112(2):407-15 [18058809.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3654-61 [16912228.001]
  • [Cites] Br J Haematol. 2003 Oct;123(2):243-52 [14531905.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Oncologist. 2007 Mar;12(3):341-55 [17405900.001]
  • [Cites] Br J Haematol. 1999 Oct;107(1):69-79 [10520026.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2009;:385-95 [20008224.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1519-32 [18024401.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jan;48(1):10-5 [16642489.001]
  • [Cites] Blood. 2009 Sep 17;114(12):2489-96 [19528532.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3686-92 [16877738.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4172-4 [17909077.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3415-22 [12885836.001]
  • [Cites] Blood. 2010 Mar 25;115(12):2372-9 [20056794.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4944-51 [18606980.001]
  • [Cites] N Engl J Med. 1999 Sep 30;341(14):1051-62 [10502596.001]
  • [Cites] Pediatr Blood Cancer. 2009 Dec;53(6):1136-9 [19618455.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):578-85 [20038731.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):624-33 [14726504.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4791-7 [18695255.001]
  • [Cites] Leukemia. 2009 Feb;23(2):262-70 [19020547.001]
  • [Cites] JAMA. 2005 Jan 12;293(2):203-11 [15644547.001]
  • [Cites] Leukemia. 2002 Apr;16(4):601-7 [11960339.001]
  • [Cites] Blood. 2003 May 1;101(9):3398-406 [12506020.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3707-16 [10572083.001]
  • [Cites] Blood. 2009 Jun 25;113(26):6558-66 [19304957.001]
  • [Cites] Best Pract Res Clin Haematol. 2009 Dec;22(4):523-8 [19959103.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1404-12 [15084614.001]
  • (PMID = 20652454.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


10. Children's Oncology Group, Aplenc R, Alonzo TA, Gerbing RB, Smith FO, Meshinchi S, Ross JA, Perentesis J, Woods WG, Lange BJ, Davies SM: Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group. Blood; 2006 Jul 1;108(1):74-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group.
  • We evaluated differences in outcome by ethnicity among children with acute myeloid leukemia (AML).
  • In conclusion, Hispanic and black children with AML have worse survival than white children.
  • Access to chemotherapy, differences in supportive care or leukemia phenotype, and reduced compliance are unlikely explanations for this difference because therapy was given intravenously according to CCG protocols.


11. Winter SS, Holdsworth MT, Devidas M, Raisch DW, Chauvenet A, Ravindranath Y, Ducore JM, Amylon MD: Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296. Pediatr Blood Cancer; 2006 Feb;46(2):179-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
  • PURPOSE: A previous Pediatric Oncology Group (POG) study showed high incidence of secondary acute myelogenous leukemia (AML) in children treated for T-cell acute lymphoblastic leukemia (T-ALL) or higher-stage lymphoblastic lymphoma.
  • One patient taken off study for asparaginase toxicity was treated with multiagent therapy that contained teniposide, and died from secondary myelodysplasia (sMDS)/AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Anthracyclines / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Asparaginase / administration & dosage. Asparaginase / adverse effects. Child. Child, Preschool. Disease-Free Survival. Drug Hypersensitivity / etiology. Female. Follow-Up Studies. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / mortality. Male. Pilot Projects. Remission Induction. Sepsis / etiology. Sepsis / mortality

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16007607.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 U10 CA5312; United States / NCI NIH HHS / CA / CA29139
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


12. Latino-Martel P, Chan DS, Druesne-Pecollo N, Barrandon E, Hercberg S, Norat T: Maternal alcohol consumption during pregnancy and risk of childhood leukemia: systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev; 2010 May;19(5):1238-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maternal alcohol consumption during pregnancy and risk of childhood leukemia: systematic review and meta-analysis.
  • BACKGROUND: Leukemia is the most frequently occurring cancer in children.
  • Although its etiology is largely unknown, leukemia is believed to result from an interaction between genetic and environmental factors.
  • METHODS: To assess the association between maternal alcohol consumption during pregnancy and childhood leukemia, a systematic review and meta-analysis of published studies was done.
  • Analyses were conducted by type of leukemia, children's age at diagnosis, and type of alcoholic beverage and trimester of pregnancy at alcohol use.
  • Alcohol intake during pregnancy (yes versus no) was statistically significantly associated with childhood acute myeloid leukemia (AML) [odds ratio (OR), 1.56; 95% confidence interval (CI), 1.13-2.15] but not with acute lymphoblastic leukemia (OR, 1.10; 95% CI, 0.93-1.29).
  • The OR of AML for an increase of a drink per week was 1.24 (95% CI, 0.94-1.64).
  • The association of alcohol intake during pregnancy with AML was observed for cancers diagnosed at age 0 to 4 years (OR, 2.68; 95% CI, 1.85-3.89) in five studies without heterogeneity (I2<or=0.1%).
  • CONCLUSIONS: The results of case-control studies indicate that maternal alcohol consumption during pregnancy is associated with a significantly increased risk of AML in young children.
  • IMPACT: Avoidance of maternal alcohol drinking during pregnancy might contribute to a decrease in the risk of childhood AML.
  • [MeSH-major] Alcohol Drinking / adverse effects. Leukemia / chemically induced. Prenatal Exposure Delayed Effects
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Mothers. Pregnancy. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 AACR
  • (PMID = 20447918.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Stubbs MC, Armstrong SA: Therapeutic implications of leukemia stem cell development. Clin Cancer Res; 2007 Jun 15;13(12):3439-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic implications of leukemia stem cell development.
  • Acute myelogenous leukemias, and perhaps many other cancers, are maintained by a population of cancer stem cells that can regenerate themselves as well as give rise to more differentiated and less proliferative cells that constitute the bulk of the disease.
  • Recent discoveries have shed light on both the nature of leukemia stem cells (LSC) and their cells of origin.
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. Hematopoietic Stem Cells / physiology. Leukemia / physiopathology. Neoplastic Stem Cells / physiology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575205.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


1
Advertisement
4. Morerio C, Acquila M, Rapella A, Tassano E, Rosanda C, Panarello C: Inversion (11)(p15q22) with NUP98-DDX10 fusion gene in pediatric acute myeloid leukemia. Cancer Genet Cytogenet; 2006 Dec;171(2):122-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inversion (11)(p15q22) with NUP98-DDX10 fusion gene in pediatric acute myeloid leukemia.
  • The inv(11)(p15q22), a rare but recurrent chromosome abnormality that creates a NUP98-DDX10 fusion gene, is associated with de novo or secondary myeloid malignancies.
  • We report a case of acute monocytic leukemia presenting this rearrangement, studied using fluorescence in situ hybridization (FISH) and reverse transcriptase-PCR (RT-PCR).
  • [MeSH-major] Chromosome Inversion. Chromosomes, Human, Pair 11 / genetics. DEAD-box RNA Helicases / genetics. Gene Fusion. Leukemia, Myeloid, Acute / genetics. Nuclear Pore Complex Proteins / genetics
  • [MeSH-minor] Child. Humans. Male. Molecular Sequence Data

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17116492.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AB040537/ AB040538
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Pore Complex Proteins; 0 / Nup98 protein, human; EC 3.6.1.- / DDX10 protein, human; EC 3.6.4.13 / DEAD-box RNA Helicases
  • [Number-of-references] 12
  •  go-up   go-down


15. Dorantes-Acosta E, Chávez-González A, Santos JI, Medina-Sanson A, Mayani H: Defective in vitro growth of primitive hematopoietic cells from pediatric patients with acute myeloid leukemia. Pediatr Blood Cancer; 2008 Dec;51(6):741-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defective in vitro growth of primitive hematopoietic cells from pediatric patients with acute myeloid leukemia.
  • BACKGROUND: Acute myeloid leukemia (AML) is a neoplastic hematologic disorder that arises at the level of a primitive stem/progenitor cell.
  • Most studies on the biology of the hematopoietic system in AML have focused on cells from adult patients; much less is known about hematopoietic cells from childhood AML.
  • PROCEDURE: By using a negative immunoselection system, we have obtained a primitive cell population (enriched for CD34(+) Lin(-) cells) from the bone marrow (BM) of 17 pediatric AML patients and characterized its proliferation, expansion, and differentiation potentials in liquid cultures supplemented with a mixture of 8 different recombinant stimulatory cytokines.
  • RESULTS: The proportion of CD34(+) cells in AML patients was extremely heterogeneous, ranging from 0% to 74%.
  • Regardless of their CD34(+) cell content, and in contrast to normal cells, AML cells showed a deficient capacity to proliferate even in the presence of the stimulatory cytokines.
  • AML progenitors were unable to generate new progenitor cells, indicating their inability to expand.
  • Interestingly, AML cells were able to differentiate in culture, giving rise to morphologically recognizable precursors.
  • A major difference, however, as compared to hematopoietic progenitors from normal subjects, was the fact that whereas in cultures of normal cells both myeloid and erythroid precursors were produced, in AML cultures the vast majority of the cells generated corresponded to myeloid cells, mostly mature macrophages.
  • CONCLUSION: As compared to their normal counterparts, primitive hematopoietic cells from pediatric patients with AML possess impaired proliferation, expansion, and differentiation potentials in vitro.
  • [MeSH-major] Bone Marrow Cells / pathology. Hematopoietic Stem Cells / pathology. Leukemia, Myeloid, Acute / blood
  • [MeSH-minor] Adolescent. Antigens, CD34 / blood. Cell Differentiation. Cell Proliferation. Cells, Cultured. Child. Child, Preschool. Cytokines / metabolism. Female. Humans. In Vitro Techniques. Male

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18680148.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Cytokines
  •  go-up   go-down


16. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X, Meshinchi S, Degar B, Airewele G, Raimondi SC, Onciu M, Coustan-Smith E, Downing JR, Leung W, Pui CH, Campana D: Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol; 2010 Jun;11(6):543-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
  • BACKGROUND: We sought to improve outcome in patients with childhood acute myeloid leukaemia (AML) by applying risk-directed therapy that was based on genetic abnormalities of the leukaemic cells and measurements of minimal residual disease (MRD) done by flow cytometry during treatment.
  • METHODS: From Oct 13, 2002, to June 19, 2008, 232 patients with de-novo AML (n=206), therapy-related or myelodysplasia-related AML (n=12), or mixed-lineage leukaemia (n=14) were enrolled at eight centres.
  • Other analyses were limited to the 216 patients with AML, excluding those with mixed-lineage leukaemia.
  • INTERPRETATION: Our findings suggest that the use of targeted chemotherapy and HSCT, in the context of a comprehensive risk-stratification strategy based on genetic features and MRD findings, can improve outcome in patients with childhood AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / pathology
  • [MeSH-minor] Adolescent. Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Cytarabine / administration & dosage. Cytogenetic Analysis. Daunorubicin / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Flow Cytometry. Humans. Infant. Infant, Newborn. Male. Neoplasm, Residual. Remission Induction. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Blood. 2001 Jan 1;97(1):56-62 [11133742.001]
  • [Cites] J Clin Oncol. 2010 Feb 20;28(6):955-9 [20085940.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3727-32 [11389009.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2302-9 [11981001.001]
  • [Cites] Lancet. 2002 May 11;359(9318):1686-9 [12020548.001]
  • [Cites] Blood. 2003 May 1;101(9):3398-406 [12506020.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):823-38 [12786792.001]
  • [Cites] Br J Haematol. 2003 Oct;123(2):243-52 [14531905.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2715-22 [14669294.001]
  • [Cites] J Chronic Dis. 1974 Sep;27(7-8):365-75 [4612056.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Biometrics. 1979 Sep;35(3):549-56 [497341.001]
  • [Cites] Blood. 1996 Mar 1;87(5):1710-7 [8634416.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4979-89 [8652810.001]
  • [Cites] Blood. 1996 Oct 15;88(8):2841-51 [8874180.001]
  • [Cites] Br J Haematol. 1998 Apr;101(1):130-40 [9576193.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2090-100 [16304571.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2130-8 [16304572.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1315-24 [16254147.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2495-502 [16639734.001]
  • [Cites] Blood. 2006 Jul 1;108(1):74-80 [16537811.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):116-24 [16721819.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3686-92 [16877738.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4499-506 [16983120.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1044-53 [18000167.001]
  • [Cites] Cancer. 2008 Jul 15;113(2):376-82 [18459178.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4944-51 [18606980.001]
  • [Cites] Blood. 2009 May 21;113(21):5083-9 [19131545.001]
  • [Cites] N Engl J Med. 2009 Jun 25;360(26):2730-41 [19553647.001]
  • [Cites] Blood. 2009 Jul 30;114(5):937-51 [19357394.001]
  • [Cites] Leukemia. 2009 Aug;23(8):1410-6 [19242495.001]
  • [Cites] J Clin Oncol. 2009 Aug 20;27(24):4007-13 [19620491.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2009;:385-95 [20008224.001]
  • [CommentIn] Lancet Oncol. 2010 Jun;11(6):502-3 [20522371.001]
  • (PMID = 20451454.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00136084
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R01 CA115422; United States / NCI NIH HHS / CA / R01 CA115422-02
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 93NS566KF7 / gemtuzumab; ZS7284E0ZP / Daunorubicin; DAV regimen
  • [Other-IDs] NLM/ NIHMS319127; NLM/ PMC3171799
  •  go-up   go-down


17. Choi HW, Shin MG, Sawyer JR, Cho D, Kee SJ, Baek HJ, Kook H, Kim HJ, Shin JH, Suh SP, Hwang TJ, Ryang DW: Unusual type of TLS/FUS-ERG chimeric transcript in a pediatric acute myelocytic leukemia with 47,XX,+10,t(16;21)(p11;q22). Cancer Genet Cytogenet; 2006 Jun;167(2):172-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual type of TLS/FUS-ERG chimeric transcript in a pediatric acute myelocytic leukemia with 47,XX,+10,t(16;21)(p11;q22).
  • We report on a case of pediatric acute myelocytic leukemia showing 47,XX,+10,t(16;21)(p11;q22) that resulted in an unusual TLS/FUS-ERG chimeric transcript.
  • The leukemic cells showed erythrophagocytosis, positive reactions for myeloperoxidase and Sudan black B stains, and negative reactions for periodic acid-Schiff and alpha-naphtyl butyrate esterase stains as well as expression of myeloid antigens.
  • [MeSH-major] Chromosomes, Human, Pair 16. Chromosomes, Human, Pair 21. Leukemia, Myeloid, Acute / genetics. Oncogene Proteins, Fusion / genetics. RNA-Binding Protein FUS / genetics. Translocation, Genetic
  • [MeSH-minor] Bone Marrow Cells / cytology. Child, Preschool. Chromosomes, Human, Pair 10. Female. Humans. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA. Trisomy

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16737920.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / RNA-Binding Protein FUS; 0 / TLS-ERG fusion protein, human
  •  go-up   go-down


18. Creutzig U, Diekamp S, Zimmermann M, Reinhardt D: Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatr Blood Cancer; 2007 Jun 15;48(7):651-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML.
  • BACKGROUND: Anthracyclines are effective antineoplastic drugs in acute myelogenous leukemia (AML).
  • PROCEDURE: To evaluate anthracycline-associated cardiomyopathy in pediatric AML-patients, the incidence of early and late (>1 year after intensive AML chemotherapy) clinical and subclinical cardiotoxicity was analyzed out of a total of 1,207 patients <18 years treated between 1993 and 2003 in trials AML-BFM93/98: 1,010 protocol patients with de novo AML, 121 with Down syndrome (DS)-AML, and 76 with secondary AML.
  • RESULTS: Thirty-eight patients (4.3%), including 3 DS-AML and 1 secondary AML, suffered from early cardiomyopathy.
  • After 5 years, four patients showed temporarily or persistently a reduced shortening fraction, which led to death in one DS-AML patient.
  • CONCLUSION: In spite of a highly intensive and effective treatment, the frequency of anthracycline-associated cardiomyopathy was low in the AML-BFM studies.
  • [MeSH-major] Anthracyclines / adverse effects. Heart / drug effects. Heart Diseases / chemically induced. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug-Related Side Effects and Adverse Reactions. Echocardiography / methods. Female. Follow-Up Studies. Humans. Infant. Longitudinal Studies. Male. Pilot Projects. Risk Factors. Survivors. Time. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • [CommentIn] Pediatr Blood Cancer. 2007 Jun 15;48(7):649-50 [17318875.001]
  • (PMID = 17183582.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines
  •  go-up   go-down


19. Shimada A, Taki T, Kubota C, Tawa A, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Hayashi Y: No nucleophosmin mutations in pediatric acute myeloid leukemia with normal karyotype: a study of the Japanese Childhood AML Cooperative Study Group. Leukemia; 2007 Jun;21(6):1307
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No nucleophosmin mutations in pediatric acute myeloid leukemia with normal karyotype: a study of the Japanese Childhood AML Cooperative Study Group.
  • [MeSH-major] Leukemia, Myeloid / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. DNA Mutational Analysis. Humans. Infant. Infant, Newborn. Japan. Karyotyping. Mutation


20. Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DK, Wheatley K, de Graaf SS, van den Berg E, Burnett AK, Gibson BE: Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol; 2010 Jun 01;28(16):2674-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12.
  • PURPOSE: Karyotype is an independent indicator of prognosis in acute myeloid leukemia (AML) that is widely applied to risk-adapted therapy.
  • Because AML is rare in children, the true prognostic significance of individual chromosomal abnormalities in this age group remains unclear.
  • PATIENTS AND METHODS: This cytogenetic study of 729 childhood patients classified them into 22 subgroups and evaluated their incidence and risk.
  • Abnormalities of 3q and complex karyotypes, in the absence of favorable-risk features, have been associated with an adverse outcome in adults, but the results were not significant in this childhood series.
  • CONCLUSION: Because the spectrum of chromosomal changes and their risk association seem to differ between children and adults with AML, biologic differences are emerging, which will contribute to the redefinition of risk stratification for different age groups in the future.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 10. Chromosomes, Human, Pair 12. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / mortality
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Child. Child, Preschool. Confidence Intervals. Cytogenetic Analysis. Disease-Free Survival. Female. Fluorescence. Genetic Predisposition to Disease / epidemiology. Humans. In Situ Hybridization. Infant. Kaplan-Meier Estimate. Karyotyping. Logistic Models. Male. Multivariate Analysis. Odds Ratio. Probability. Prognosis. Proportional Hazards Models. Registries. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. United Kingdom


21. Kobayashi R, Tawa A, Hanada R, Horibe K, Tsuchida M, Tsukimoto I, Japanese childhood AML cooperative study group: Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia. Pediatr Blood Cancer; 2007 Apr;48(4):393-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia.
  • BACKGROUND: Extramedullary infiltration (EMI) is an occasional clinical symptom in childhood acute myelogenous leukemia (AML), but there is considerable controversy regarding the prognostic significance of EMI in AML.
  • PROCEDURE: We evaluated the frequency and prognostic significance of EMI at diagnosis of AML in children.
  • RESULTS: Of 240 cases of de novo AML excluding children with Down syndrome and acute promyelocytic leukemia, 56 (23.3%) showed EMI at diagnosis.
  • CONCLUSIONS: CNS leukemia and EMI together with a WBC count of >100 x 10(9)/L at diagnosis of AML are high risk factors for relapse, and alternative treatment approaches for patients with these characteristics should be explored.
  • [MeSH-major] Leukemia, Myeloid / pathology. Leukemic Infiltration / epidemiology. Sarcoma, Myeloid / epidemiology
  • [MeSH-minor] Acute Disease. Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone and Bones / pathology. Central Nervous System / pathology. Child. Child, Preschool. Cytarabine / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Follow-Up Studies. Gingiva / pathology. Humans. Hydrocortisone / administration & dosage. Idarubicin / administration & dosage. Infant. Infant, Newborn. Japan / epidemiology. Kaplan-Meier Estimate. Male. Methotrexate / administration & dosage. Orbit / pathology. Prognosis. Remission Induction. Skin / pathology. Testis / pathology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550530.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate; ZRP63D75JW / Idarubicin
  •  go-up   go-down


22. Shimada A, Ichikawa H, Taki T, Kubota C, Hongo T, Sako M, Morimoto A, Tawa A, Tsukimoto I, Hayashi Y: Low frequency of KIT gene mutation in pediatric acute myeloid leukemia with inv(16)(p13q22): a study of the Japanese Childhood AML Cooperative Study Group. Int J Hematol; 2007 Oct;86(3):289-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low frequency of KIT gene mutation in pediatric acute myeloid leukemia with inv(16)(p13q22): a study of the Japanese Childhood AML Cooperative Study Group.
  • [MeSH-major] Chromosome Inversion. Leukemia, Myeloid, Acute / genetics. Proto-Oncogene Proteins c-kit / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Male. Survival Rate


23. Styczynski J, Wysocki M, Dluzniewska A, Juraszewska E, Balwierz W, Czyzewski K, Wieczorek M, Olejnik I, Krawczuk-Rybak M, Kuzmicz M, Kowalczyk J, Stefaniak J, Badowska W, Sonta-Jakimczyk D, Szczepanski T, Matysiak M, Stanczak E, Malinowska I, Wachowiak J, Konatkowska B, Gil L, Balcerska A, Kapuscinska L, Szczepanek J, Kolodziej B, Rafinska B, Kubicka M: Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia. Anticancer Res; 2008 May-Jun;28(3B):1927-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia.
  • BACKGROUND: The role of cellular drug resistance in childhood acute myeloid leukemia (AML) has not yet been established.
  • The aim of the study was the analysis of the clinical value of ex vivo drug resistance in pediatric AML.
  • PATIENTS AND METHODS: A cohort of 90 children with de novo AML were assayed for drug resistance profile by the 3-4,5-dimethylthiazol-2-yl-2,5-difenyl tetrazolium bromide (MTT) assay and prognostic model of in vitro drug sensitivity was analyzed.
  • A combined in vitro drug resistance profile to fludarabine, treosulfan and mitoxantrone (FTM score) was defined and it had an independent prognostic significance for disease free survival in pediatric AML.
  • CONCLUSION: The combined fludarabine, treosulfan and mitoxantrone resistance profile to possibly may be used for better stratification of children with AML or indicate the necessity for additional therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Busulfan / administration & dosage. Busulfan / analogs & derivatives. Child. Child, Preschool. Cohort Studies. Drug Resistance, Neoplasm. Drug Screening Assays, Antitumor. Female. Humans. Infant. Male. Mitoxantrone / administration & dosage. Prognosis. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Childhood.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. TREOSULFAN .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630483.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] BZ114NVM5P / Mitoxantrone; CO61ER3EPI / treosulfan; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
  •  go-up   go-down


24. Roman E, Cooney E, Harrison L, Militano O, Wolownik K, Hawks R, Foley S, Satwani P, Unal E, Bhatia M, Bradley B, Del Toro G, George D, Garvin J, van de Ven C, Cairo MS: Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clin Cancer Res; 2005 Oct 1;11(19 Pt 2):7164s-7170s
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
  • PURPOSE: Myeloablative allogeneic stem cell transplantation (SCT) has been successful in the treatment of childhood acute myeloid leukemia (AML), but may be associated with significant toxicity and recurrent disease.
  • Reduced-intensity allogeneic SCT may offer a less toxic approach to patients with AML.
  • Targeted immunotherapy with gemtuzumab ozogamicin has been shown to be safe, well tolerated in children, and, as a single agent, gemtuzumab ozogamicin has induced responses in 30% of patients with recurrent CD33+ AML.
  • Therefore, we explored the feasibility and toxicity of targeted immunotherapy following reduced-intensity allogeneic SCT in children with CD33+ AML.
  • EXPERIMENTAL DESIGN: Eight patients with CD33+ AML received a reduced-intensity allogeneic SCT following fludarabine 30 mg/m2 for 6 days and busulfan 3.2 mg/kg (<4 years, 4 mg/kg/d) for 2 days.
  • CONCLUSIONS: The administration of gemtuzumab ozogamicin post reduced-intensity allogeneic SCT in children with average risk AML is feasible and well tolerated with minimal toxicity.
  • The maximal tolerated dose has yet to be determined for gemtuzumab ozogamicin post reduced-intensity allogeneic SCT in children with CD33+ AML.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antigens, CD / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. Immunotherapy / methods. Leukemia, Myeloid, Acute / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Antibodies, Monoclonal, Humanized. Busulfan / administration & dosage. Child. Child, Preschool. Combined Modality Therapy. Female. Graft vs Host Disease / prevention & control. Histocompatibility Testing. Humans. Infant. Male. Pilot Projects. Recurrence. Sialic Acid Binding Ig-like Lectin 3. Time Factors. Transplantation Conditioning. Transplantation, Homologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203817.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / T32 HL07968
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / gemtuzumab; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
  •  go-up   go-down


25. Smith WJ, Drew RH, Perfect JR: Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update. Expert Rev Anti Infect Ther; 2009 Mar;7(2):165-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pharmacokinetic data in special patient populations (such as neutropenic patients with acute myelogenous leukemia or myelodysplastic syndrome, allogeneic hematopoietic stem cell transplant recipients, febrile neutropenic patients and pediatric patients) have been published recently.

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19254165.001).
  • [ISSN] 1744-8336
  • [Journal-full-title] Expert review of anti-infective therapy
  • [ISO-abbreviation] Expert Rev Anti Infect Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Triazoles; 6TK1G07BHZ / posaconazole
  • [Number-of-references] 115
  •  go-up   go-down


26. Ashfaq K, Yahaya I, Hyde C, Andronis L, Barton P, Bayliss S, Chen YF: Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review. Health Technol Assess; 2010 Dec;14(54):iii-iv, ix-xi, 1-141
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review.
  • BACKGROUND: Acute leukaemia is a group of rapidly progressing cancers of bone marrow and blood classified as either acute myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL).
  • OBJECTIVES: A systematic overview of the best available evidence on the clinical effectiveness and cost-effectiveness of SCT in the treatment of acute leukaemia.
  • Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.
  • Although there is a wealth of information on costs and some information on cost-effectiveness of allogeneic SCT in adults with AML (DPs 1 and 2), there is very limited evidence on relative costs and cost-effectiveness for other DPs.
  • CONCLUSIONS: Bearing in mind the limitations, existing evidence suggests that sibling donor allogeneic SCT may be more effective than chemotherapy in adult AML (except in good-risk patients) in CR1, childhood AML in CR1 and adult ALL in CR1, and that autologous SCT is equal to or less effective than chemotherapy.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
  • [MeSH-minor] Adult. Child. Cost-Benefit Analysis. Humans


27. Sung L, Gamis A, Alonzo TA, Buxton A, Britton K, Deswarte-Wallace J, Woods WG: Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. Cancer; 2009 Mar 1;115(5):1100-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia.
  • BACKGROUND: The objectives were to compare infections during different intensities of therapy in children with acute myeloid leukemia (AML).
  • METHODS: Subjects were children enrolled in Children's Cancer Group 2891 with AML.
  • This information sheds insight into the mechanisms behind susceptibility and outcome of infections in pediatric AML.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • [Cites] J Clin Oncol. 2000 May;18(9):1845-55 [10784625.001]
  • [Cites] Blood. 2001 Jan 1;97(1):56-62 [11133742.001]
  • [Cites] Clin Infect Dis. 2002 Jan 1;34(1):7-14 [11731939.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Nov;24(8):627-35 [12439034.001]
  • [Cites] Leukemia. 2004 Jan;18(1):72-7 [14586478.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4384-93 [15514380.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4979-89 [8652810.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1179-87 [9508206.001]
  • [Cites] Br J Haematol. 1999 Aug;106(2):436-44 [10460604.001]
  • [Cites] JAMA. 2005 Jan 12;293(2):203-11 [15644547.001]
  • [Cites] Ann Intern Med. 2005 Jun 21;142(12 Pt 1):979-95 [15968013.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5207-15 [17114653.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3532-9 [17660380.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1044-53 [18000167.001]
  • [ErratumIn] Cancer. 2009 Jun 15;115(12):2807
  • (PMID = 19156894.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543-06; United States / NCI NIH HHS / CA / U10 CA098413-06; United States / NCI NIH HHS / CA / U10 CA095861-08; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA095861; United States / NCI NIH HHS / CA / U10 CA098543; None / None / / U10 CA098413-06; United States / NCI NIH HHS / CA / U10 CA095861-06; United States / NCI NIH HHS / CA / CA095861-06; None / None / / U10 CA098543-06
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS107661; NLM/ PMC2677372
  •  go-up   go-down


28. Klingebiel T, Reinhardt D, Bader P, EBMT Paediatric Diseases Working Party: Place of HSCT in treatment of childhood AML. Bone Marrow Transplant; 2008 Oct;42 Suppl 2:S7-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Place of HSCT in treatment of childhood AML.
  • This short review focuses on the role of hematopoietic SCT (HSCT) in childhood AML.
  • Data on haploidentical HSCT and on cord blood HSCT are still lacking in the case of AML.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Living Donors
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Clinical Trials as Topic. Disease-Free Survival. Humans. Infant. Remission Induction. Siblings. Survival Rate. Transplantation, Autologous. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18978749.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 15
  •  go-up   go-down


29. Shah M, Agarwal B: Recent advances in management of acute myeloid leukemia (AML). Indian J Pediatr; 2008 Aug;75(8):831-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in management of acute myeloid leukemia (AML).
  • Acute myeloid leukemia (AML) is the most common childhood malignancy.
  • AML has therapeutically been difficult to treat.
  • In 2001, the World Health Organization (WHO), in conjunction with the Society for Hematopathology and the European Association of Hematopathology, published a new classification for myeloid neoplasms.
  • A number of chromosomal abnormalities are used to predict outcome and stratify therapeutic risk groups in children with AML.
  • Recently, alterations in receptor tyrosine kinases, tyrosine phosphatases and in oncogenes such as RAS have been implicated in the pathogenesis of AML.
  • This article aims to review the recent development in diagnosis, treatment and monitoring of AML.
  • Better understanding of the molecular pathogenesis of AML has led to the development of target-specific therapies.
  • The role of allogenic SCT, particularly whether it should be done during first CR or reserved for second remission, remains the most controversial issue in pediatric AML.
  • There is a need of collaboration with international pediatric cooperative oncology groups and definitive clinical trials in order to establish use of these newer molecules in pediatric populations.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Immunologic Factors / therapeutic use. Leukemia, Myeloid, Acute / therapy. Neoplasm, Residual / drug therapy
  • [MeSH-minor] Antigens, CD / blood. Antigens, Differentiation, Myelomonocytic / blood. Child. Child, Preschool. Humans. Prognosis. Remission Induction. Sialic Acid Binding Ig-like Lectin 3. fms-Like Tyrosine Kinase 3 / antagonists & inhibitors. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1494-504 [12406902.001]
  • [Cites] Br J Haematol. 1998 Apr;101(1):130-40 [9576193.001]
  • [Cites] Blood. 2007 Aug 1;110(3):979-85 [17440048.001]
  • [Cites] Blood. 2007 Feb 15;109 (4):1387-94 [17082323.001]
  • [Cites] Haematologica. 1990 Mar-Apr;75(2):159-69 [2192943.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1490-6 [11410481.001]
  • [Cites] Blood. 2003 Aug 1;102(3):795-801 [12649163.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1183-8 [15886328.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2130-8 [16304572.001]
  • [Cites] Leukemia. 2001 Mar;15(3):348-54 [11237056.001]
  • [Cites] Blood. 1991 Nov 15;78(10):2520-6 [1824249.001]
  • [Cites] Blood. 1992 Jun 15;79(12):3267-73 [1596567.001]
  • [Cites] Curr Opin Oncol. 2003 Jan;15(1):23-35 [12490758.001]
  • [Cites] Blood. 2004 May 15;103(10):3669-76 [14726387.001]
  • [Cites] Blood. 2005 Jan 1;105(1):54-60 [15345597.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4173-9 [9751631.001]
  • [Cites] Pediatr Clin North Am. 2008 Feb;55(1):21-51, ix [18242314.001]
  • [Cites] Blood. 2005 Feb 1;105(3):986-93 [15459012.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3654-61 [16912228.001]
  • [Cites] Blood Cells Mol Dis. 2008 Mar-Apr;40(2):192-9 [17905612.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1843-8 [12685842.001]
  • [Cites] Klin Padiatr. 2002 Jul-Aug;214(4):188-94 [12165900.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2025-9 [16304569.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1519-32 [18024401.001]
  • [Cites] Br J Haematol. 1999 Sep;106(4):860-9 [10519985.001]
  • [Cites] Leukemia. 1996 Oct;10(10):1563-9 [8847890.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4217-24 [12377965.001]
  • [Cites] Br J Clin Pharmacol. 2003 Oct;56(4):370-7 [12968981.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2708-16 [12351376.001]
  • [Cites] Haematologica. 2006 Mar;91(3):419-21 [16531270.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1919-28 [18450603.001]
  • [Cites] Haematol Blood Transfus. 1987;30:71-5 [3305225.001]
  • [Cites] Onkologie. 2004 Jun;27(3):269-72 [15249716.001]
  • [Cites] Leuk Res. 2004 Apr;28(4):349-52 [15109533.001]
  • [Cites] Pediatr Blood Cancer. 2007 Aug;49(2):127-32 [16807916.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6525-8 [2208112.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(5):707-21, discussion 722-4 [15010072.001]
  • [Cites] Bone Marrow Transplant. 2002 May;29(10):843-52 [12058234.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1909-18 [18450602.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2804-11 [11387351.001]
  • [Cites] Leukemia. 2000 Jul;14(7):1201-7 [10914543.001]
  • (PMID = 18769895.001).
  • [ISSN] 0973-7693
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Immunologic Factors; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Number-of-references] 43
  •  go-up   go-down


30. Gupta VB, Willert J, Pian M, Stein MT: When disclosing a serious diagnosis to a minor conflicts with family values. J Dev Behav Pediatr; 2008 Jun;29(3):231
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An 11-year old Asian-Indian boy was recently discovered to have acute myelogenous leukemia.
  • The pediatric hematologist-oncologist arranged a meeting to inform the parents about the diagnosis, prognosis and treatment.
  • The physician planned to include the child in this process.
  • However, the child's father, a computer programmer, made a request that his son should not be informed about the diagnosis of leukemia.
  • The oncologist then informed the father that, as a physician, she has the responsibility to truthfully disclose the diagnosis to a patient, and she insisted on informing the child about the leukemia in an open and truthful manner.
  • [MeSH-major] Conflict (Psychology). Ethics, Medical. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / psychology. Minors / psychology. Professional-Family Relations / ethics. Social Values / ethnology. Truth Disclosure / ethics
  • [MeSH-minor] Child. Communication. Cultural Characteristics. Deception. Fathers / psychology. Humans. India / ethnology. Male. Personal Autonomy. Physician-Patient Relations. Terminal Care / ethics. Terminal Care / psychology. Trust

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Medical Ethics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintIn] J Dev Behav Pediatr. 2010 Apr;31(3 Suppl):S100-2 [20414057.001]
  • (PMID = 18550993.001).
  • [ISSN] 0196-206X
  • [Journal-full-title] Journal of developmental and behavioral pediatrics : JDBP
  • [ISO-abbreviation] J Dev Behav Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Marques-Salles Tde J, Mkrtchyan H, Leite EP, Soares-Ventura EM, Muniz MT, Silva EF, Liehr T, Silva ML, Santos N: Complex karyotype defined by molecular cytogenetic FISH and M-FISH in an infant with acute megakaryoblastic leukemia and neurofibromatosis. Cancer Genet Cytogenet; 2010 Jul 15;200(2):167-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complex karyotype defined by molecular cytogenetic FISH and M-FISH in an infant with acute megakaryoblastic leukemia and neurofibromatosis.
  • Acute myeloid leukemia in childhood is a heterogeneous group of diseases, and different epidemiologic factors are involved in the etiopathogenesis.
  • Genetic syndromes are one of the predisposing factors of acute myeloid leukemia (AML), including Down syndrome, Bloom syndrome, and neurofibromatosis.
  • Acute megakaryoblastic leukemia (AMKL) is the main subtype in Down syndrome infants, and acquired chromosomal anomalies are closely related to the physiopathology of the illness.
  • [MeSH-major] In Situ Hybridization, Fluorescence / methods. Leukemia, Megakaryoblastic, Acute / genetics. Neurofibromatoses / genetics
  • [MeSH-minor] Female. Genes, p53. Histone-Lysine N-Methyltransferase. Humans. Infant. Karyotyping. Myeloid-Lymphoid Leukemia Protein / genetics

  • Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.
  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Neurofibromatosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20620601.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


32. Oliansky DM, Rizzo JD, Aplan PD, Arceci RJ, Leone L, Ravindranath Y, Sanders JE, Smith FO 3rd, Wilmot F, McCarthy PL Jr, Hahn T: The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. Biol Blood Marrow Transplant; 2007 Jan;13(1):1-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review.
  • Clinical research examining the role of hematopoietic stem cell transplantation (SCT) in the therapy of acute myeloid leukemia (AML) in children is presented and critically evaluated in this systematic evidence-based review.
  • Treatment recommendations based on the evidence are presented in the table entitled "Summary of Treatment Recommendations Made by the Expert Panel for Pediatric Acute Myeloid Leukemia" and were reached unanimously by a panel of experts in AML.
  • The identified priority areas of needed future research in pediatric AML include: What is the role of risk group stratification, including the role of cytogenetics, in selection of patients for allogeneic SCT, especially those in first CR?
  • and What is the role of biologically targeted agents (ie, tyrosine kinase inhibitors, farnesyl transferase inhibitors, Flt-3 inhibitors, etc) in the treatment of AML, including induction, consolidation, conditioning regimens, and after SCT?
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid / therapy. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Bone Marrow Transplantation. Child. Child, Preschool. Evidence-Based Medicine. Humans. Remission Induction / methods. Transplantation Conditioning / methods. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222748.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 69
  •  go-up   go-down


33. Mehta PA, Gerbing RB, Alonzo TA, Elliott JS, Zamzow TA, Combs M, Stover E, Ross JA, Perentesis JP, Meschinchi S, Lange BJ, Davies SM: FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group report. Clin Cancer Res; 2008 Dec 1;14(23):7896-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group report.
  • Previous work has shown increased risk of developing acute myeloid leukemia (AML) in adult patients with a variant allele at this site.
  • The same authors have shown that the presence of an adenine residue rather than a guanine residue at -1,377 bp significantly attenuates transcription factor stimulatory protein 1 binding and may contribute to a reduction in FAS expression and ultimately to the enrichment of apoptosis-resistant clones in AML.
  • We hypothesized that FAS genotype by altering susceptibility to apoptosis might affect outcome of childhood AML therapy.
  • EXPERIMENTAL DESIGN: Four hundred forty-four children treated for de novo AML on a uniform protocol were genotyped for FAS 1377.
  • CONCLUSIONS: FAS 1377 genotype does not alter outcome of de novo AML in children.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Childhood.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Med (Berl). 2000;78(6):312-25 [11001528.001]
  • [Cites] JAMA. 2005 Jan 12;293(2):203-11 [15644547.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):150-6 [14701777.001]
  • [Cites] J Exp Med. 1989 May 1;169(5):1747-56 [2469768.001]
  • [Cites] Cell. 1991 Jul 26;66(2):233-43 [1713127.001]
  • [Cites] Blood. 1992 Mar 1;79(5):1291-8 [1536952.001]
  • [Cites] J Biol Chem. 1992 May 25;267(15):10709-15 [1375228.001]
  • [Cites] J Biol Chem. 1993 May 25;268(15):10932-7 [7684370.001]
  • [Cites] Cell. 1994 Mar 25;76(6):969-76 [7511063.001]
  • [Cites] Science. 1995 Jun 2;268(5215):1347-9 [7539157.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3848-60 [7579353.001]
  • [Cites] J Exp Med. 1998 Jun 1;187(11):1825-38 [9607923.001]
  • [Cites] Immunity. 1998 Jul;9(1):47-57 [9697835.001]
  • [Cites] Exp Hematol. 1999 May;27(5):868-74 [10340403.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3068-72 [10397246.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):8101-8 [15520222.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4327-30 [12907599.001]
  • (PMID = 19047119.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543-06; United States / NCI NIH HHS / CA / R01 CA093552-01; United States / NCI NIH HHS / CA / R01 CA093552; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / R01 CA 76326-01; None / None / / U10 CA098543-06; United States / NCI NIH HHS / CA / CA093552-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95
  • [Other-IDs] NLM/ NIHMS103099; NLM/ PMC2787450
  •  go-up   go-down


34. Khare RK, Settimi PD, Mba NI, Wechsler DS, Bratton SL, Williams DM: Aortobronchial fistula in a pediatric patient with massive hemoptysis: treatment by means of an aortic endograft. Ann Thorac Surg; 2005 Aug;80(2):731-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aortobronchial fistula in a pediatric patient with massive hemoptysis: treatment by means of an aortic endograft.
  • We present an 11-year-old girl with acute myelogenous leukemia and hemoptysis from abscess erosion into the descending thoracic aorta.
  • We report a pediatric case of an aortobronchial fistula treated with an aortic endograft and discuss the technical limitations and potential complications of this procedure.
  • [MeSH-minor] Antifungal Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Aortography. Child. Embolization, Therapeutic. Female. Hemoptysis / etiology. Humans. Leukemia, Myeloid, Acute / drug therapy. Lung Abscess / complications. Lung Abscess / microbiology. Lung Abscess / therapy. Pneumonectomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16039247.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


35. Castellino SM, Alonzo TA, Buxton A, Gold S, Lange BJ, Woods WG: Outcomes in childhood AML in the absence of transplantation in first remission--Children's Cancer Group (CCG) studies 2891 and CCG 213. Pediatr Blood Cancer; 2008 Jan;50(1):9-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes in childhood AML in the absence of transplantation in first remission--Children's Cancer Group (CCG) studies 2891 and CCG 213.
  • BACKGROUND: The majority of childhood acute myeloid leukemia (AML) patients lack a matched-related bone marrow transplant (BMT) donor in first remission.
  • PROCEDURE: Disease-free survival (DFS), overall survival (OS), relapse-free survival (RFS), and post-relapse outcome were evaluated for children with de novo AML on CCG 213 and the standard timing (ST) and intensive timing (IT) induction arms of CCG 2891 who were randomized to (intent-to-treat, ITT) or who received (as-treated, AT) only chemotherapy intensification.
  • Overall survival for childhood AML in the absence of BMT in CR1 is influenced by duration of CR1 and by race.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Child. Disease-Free Survival. Female. Humans. Male. Remission Induction. Survival Analysis. Survival Rate

  • Genetic Alliance. consumer health - Childhood Cancer.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17252564.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 13539; United States / NCI NIH HHS / CA / CA 98543
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


36. Dawczynski K, Steinbach D, Wittig S, Pfaffendorf N, Kauf E, Zintl F: Expression of components of the IGF axis in childhood acute myelogenous leukemia. Pediatr Blood Cancer; 2008 Jan;50(1):24-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of components of the IGF axis in childhood acute myelogenous leukemia.
  • PROCEDURE: We analyzed the mRNA expression profile of IGF-I, -II, and IGFBP-2, -3 in 50 children with previously untreated AML (mean age 10.8 +/- 4.8 years; patients in CCR n = 20, patients with relapse during later course of disease n = 15).
  • RESULTS: IGFBP-2 expression was significantly higher in AML cells than in healthy cells of peripheral MNC (P < 0.001) and of bone marrow cells (P < 0.01).
  • Conversely, AML cells showed significantly lower IGFBP-3 and IGF-I gene expression compared to controls (P = 0.02; P < 0.001).
  • CONCLUSIONS: Results identified different expressions of IGF components between normal and AML cells.
  • [MeSH-major] Insulin-Like Growth Factor Binding Protein 2 / metabolism. Insulin-Like Growth Factor Binding Protein 3 / metabolism. Insulin-Like Growth Factor I / metabolism. Insulin-Like Growth Factor II / metabolism. Leukemia, Myeloid, Acute / metabolism
  • [MeSH-minor] Child. Disease-Free Survival. Gene Expression. Humans. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17635002.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / RNA, Messenger; 67763-96-6 / Insulin-Like Growth Factor I; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


37. Kardos G, Zwaan CM, Kaspers GJ, de-Graaf SS, de Bont ES, Postma A, Bökkerink JP, Weening RS, van der Does-van den Berg A, van Wering ER, Korbijn C, Hählen K: Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials. Leukemia; 2005 Dec;19(12):2063-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials.
  • This report describes the long-term follow-up data of three consecutive Dutch Childhood Oncology Group acute myeloid leukemia (AML) protocols.
  • A total of 303 children were diagnosed with AML, of whom 209 were eligible for this report.
  • The first study was the AML-82 protocol.
  • Study AML-87 was based on the BFM-87 protocol, with prophylactic cranial irradiation in high-risk patients only, and without maintenance therapy.
  • The subsequent study AML-92/94 consisted of a modified BFM-93 protocol, that is, without maintenance therapy and prophylactic cranial irradiation.
  • Our results demonstrate that outcome in childhood AML is still unsatisfactory, and that further intensification of therapy carries the risk of enhanced toxicity.
  • Our patients are currently included in the MRC AML studies, based on the results of their AML 10 trial.
  • [MeSH-major] Antineoplastic Protocols / standards. Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Cranial Irradiation. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Infant. Infant, Newborn. Male. Recurrence. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Childhood.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16107896.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  •  go-up   go-down


38. Velardi A, Ruggeri L, Mancusi A, Aversa F, Christiansen FT: Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Curr Opin Immunol; 2009 Oct;21(5):525-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia.
  • Donor-versus-recipient natural killer (NK) cell alloreactivity has been established as a key therapeutic element in HLA haplotype mismatched hematopoietic transplants in adult AML and pediatric ALL and as a possible beneficial effector in cord blood transplant for AML.
  • At present NK cell allotherapy for leukemia is deployed through stem cell transplantation (and ensuing NK cell reconstitution) across KIR ligand mismatches.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Killer Cells, Natural / immunology. Leukemia, Myeloid / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Acute Disease. Adult. Child. Humans. Immunotherapy / methods. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19717293.001).
  • [ISSN] 1879-0372
  • [Journal-full-title] Current opinion in immunology
  • [ISO-abbreviation] Curr. Opin. Immunol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 PO1 CA100265
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 46
  •  go-up   go-down


39. Mejía-Aranguré JM, Bonilla M, Lorenzana R, Juárez-Ocaña S, de Reyes G, Pérez-Saldivar ML, González-Miranda G, Bernáldez-Ríos R, Ortiz-Fernández A, Ortega-Alvarez M, Martínez-García Mdel C, Fajardo-Gutiérrez A: Incidence of leukemias in children from El Salvador and Mexico City between 1996 and 2000: population-based data. BMC Cancer; 2005;5:33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: There are very few studies that report the incidence of acute leukemias in children in Latin America.
  • This work assesses the incidence of acute leukemias, between 1996 and 2000, in children from 0-14 years old who were attended at the Mexican Social Security Institute in Mexico City and in children from 0-11 years old in El Salvador.
  • The Pediatric Hospital and the General Hospital of the Mexican Social Security Institute in Mexico City, the only centers in Mexico City which attend all those children with acute leukemia who have a right to this service.
  • DIAGNOSIS: All patients were diagnosed by bone marrow smear and were divided into acute lymphoid leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and unspecified leukemias (UL).
  • AAIRs in Mexico City were 44.9, 10.6, 2.5, 0.5, and 58.4 per million children for ALL, AML, CML, UL, and total leukemias, respectively.
  • The incidence rates for the Salvadorian group of 0-11 year olds were 34.2, 7.1, 0.6, 0.2, and 43.2 per million children for ALL, AML, CML, UL, and total leukemias, respectively.
  • [MeSH-major] Leukemia / diagnosis. Leukemia / epidemiology
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. El Salvador. Hospital Records. Humans. Incidence. Infant. Infant, Newborn. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / epidemiology. Mexico. Population. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Prevalence

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Panam Salud Publica. 1999 Aug;6(2):75-88 [10574008.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):1070-9 [10491536.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Nov-Dec;22(6):495-501 [11132215.001]
  • [Cites] Salud Publica Mex. 2000 Sep-Oct;42(5):431-7 [11125628.001]
  • [Cites] Curr Opin Pediatr. 2001 Feb;13(1):1-9 [11176236.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1402-8 [11283943.001]
  • [Cites] Eur J Cancer. 2001 Apr;37(6):695-702 [11311643.001]
  • [Cites] Med Pediatr Oncol. 2001 Oct;37(4):400-4 [11568906.001]
  • [Cites] Environ Health Perspect. 2002 Mar;110(3):319-24 [11882484.001]
  • [Cites] Med Pediatr Oncol. 2002 Jul;39(1):25-31 [12116075.001]
  • [Cites] Paediatr Perinat Epidemiol. 2002 Jul;16(3):210-8 [12123433.001]
  • [Cites] Med Pediatr Oncol. 2002 Dec;39(6):554-7; discussion 552-3 [12376977.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):639-49 [12951583.001]
  • [Cites] Br J Cancer. 2004 May 4;90(9):1771-6 [15150603.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):1-3 [15226760.001]
  • [Cites] BMC Cancer. 2004 Aug 13;4:50 [15310396.001]
  • [Cites] Bol Med Hosp Infant Mex. 1993 Apr;50(4):248-57 [8471171.001]
  • [Cites] East Afr Med J. 1994 Apr;71(4):223-5 [8062767.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 May;17(2):94-100 [7749772.001]
  • [Cites] Blood. 1996 Jan 1;87(1):308-13 [8547657.001]
  • [Cites] Arch Med Res. 1996 Summer;27(2):223-7 [8696068.001]
  • [Cites] Blood. 1996 Jul 1;88(1):377 [8704198.001]
  • [Cites] Blood. 1997 Jan 1;89(1):348-9 [8978313.001]
  • [Cites] Med Pediatr Oncol. 1997 Sep;29(3):208-12 [9212846.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 16;91(12):1051-8 [10379968.001]
  • [Cites] Blood. 2000 Jul 1;96(1):24-33 [10891426.001]
  • (PMID = 15807901.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1090561
  •  go-up   go-down


40. Willasch AM, Gruhn B, Coliva T, Kalinova M, Schneider G, Kreyenberg H, Steinbach D, Weber G, Hollink IH, Zwaan CM, Biondi A, van der Velden VH, Reinhardt D, Cazzaniga G, Bader P, Trka J, European Study Group on WT1 Expression in Childhood AML: Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. Leukemia; 2009 Aug;23(8):1472-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study.
  • A standardized, sensitive and universal method for minimal residual disease (MRD) detection in acute myeloid leukemia (AML) is still pending.
  • Although hyperexpression of Wilms' tumor (WT1) gene transcript has been frequently proposed as an MRD marker in AML, wide comparability of the various methods used for evaluating WT1 expression has not been given.
  • In a series of quality-control rounds, we analyzed 69 childhood AML samples and 47 normal bone marrow (BM) samples from 4 participating centers.
  • In AML samples, the median WT1/1E+04 Abelson (ABL) expression was 3.5E+03 compared with that of 2.3E+01 in healthy BM samples.
  • As 11.5% of childhood AML samples in this cohort harbored WT1 mutations in exon 7, the effect of mutations on WT1 expression has been investigated, showing that mutated cases expressed significantly higher WT1 levels than wild-type cases.
  • [MeSH-major] Bone Marrow Examination / standards. Genes, Wilms Tumor. Leukemia, Myeloid / pathology. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction / standards
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Child. Child, Preschool. Cohort Studies. DNA Primers. Exons / genetics. Female. Gene Expression Regulation, Leukemic. Humans. Infant. Male. Middle Aged. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Neoplasm, Residual. Sensitivity and Specificity. WT1 Proteins / biosynthesis. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19322206.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / WT1 Proteins
  •  go-up   go-down


41. Hayashi Y: [Prognostic molecular marker and molecular targeted-therapy in pediatric malignancies]. Gan To Kagaku Ryoho; 2007 Feb;34(2):194-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic molecular marker and molecular targeted-therapy in pediatric malignancies].
  • Recent progress in molecular biology has led to an increase of prognostic markers and development of molecular-targeted therapy in pediatric malignancies.
  • Recently, all-trans retinoic acid (ATRA) for acute promyeloblastic leukemia, imatinib for chronic myeloid leukemia, and rituximab for B-cell malignant lymphoma serve to improve the clinical outcome of these patients.
  • For pediatric malignancies, in addition to molecular-targeted therapy against leukemia, molecular-targeted therapies, mainly tyrosin kinase inhibitors, were applied to neuroblastoma and various types of sarcomas.
  • Recent progress in prognostic molecular marker and molecular-targeted therapy against pediatric malignancies was here reviewed.
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Benzamides. Child. Humans. Imatinib Mesylate. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Promyelocytic, Acute / drug therapy. Loss of Heterozygosity. P-Glycoprotein / genetics. Piperazines / therapeutic use. Prognosis. Pyrimidines / therapeutic use. Quinolones / therapeutic use. Rituximab. Tretinoin / therapeutic use. fms-Like Tyrosine Kinase 3 / antagonists & inhibitors

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301526.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Enzyme Inhibitors; 0 / P-Glycoprotein; 0 / Piperazines; 0 / Pyrimidines; 0 / Quinolones; 192185-72-1 / tipifarnib; 4F4X42SYQ6 / Rituximab; 5688UTC01R / Tretinoin; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


42. Fazlina N, Maha A, Jamal R, Zarina AL, Cheong SK, Hamidah H, Ainoon O, Zulkifli SZ, Hamidah NH: Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias. Hematology; 2007 Feb;12(1):33-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
  • The expression of the multidrug resistance (MDR) proteins may influence the outcome of treatment in patients with acute leukemia.
  • A total of 82 newly diagnosed acute leukemia cases (43 adult myeloid leukaemia, AML cases and 39 acute lymphoblastic leukaemia, ALL cases) and 16 relapsed cases (8 AML cases and 8 ALL cases) were studied.
  • In newly diagnosed cases, we found that childhood ALL samples showed higher IC50 values of dnr (0.040 +/- 2.320) compared to adult AML samples (0.021 +/- 0.158).
  • In contrast, newly diagnosed adult AML samples showed higher IC50 values of ara-C (0.157 +/- 0.529) compared to childhood ALL samples (0.100 +/- 2.350).
  • In relapsed cases, two samples of childhood ALL showed IC50 values of dnr (0.910 +/- 1.760) and ara-C (1.310 +/- 2.390), which was higher compared to childhood AML samples (0.129 +/- 0.214 and 0.210 +/- 0.003, respectively).
  • In conclusion, we found that MTS assay is an easy, rapid and non laborious method to study in vitro drug resistance in acute leukaemia cases.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Leukemia / metabolism. Neoplasm Proteins / metabolism. P-Glycoproteins / metabolism
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Cell Survival. Child. Child, Preschool. Coloring Agents / analysis. Cytarabine / pharmacology. Daunorubicin / pharmacology. Female. Humans. Infant. Inhibitory Concentration 50. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / metabolism. Male. Methylphenazonium Methosulfate / pharmacology. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Recurrence. Staining and Labeling / methods. Tetrazolium Salts / analysis. Thiazoles / analysis. Treatment Outcome. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / ultrastructure

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17364990.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Coloring Agents; 0 / Neoplasm Proteins; 0 / P-Glycoproteins; 0 / Tetrazolium Salts; 0 / Thiazoles; 04079A1RDZ / Cytarabine; 138169-43-4 / 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; 299-11-6 / Methylphenazonium Methosulfate; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


43. Al-Shehri A, Al-Seraihy A, Owaidah TM, Belgaumi AF: Megakaryocytic blast crisis at presentation in a pediatric patient with chronic myeloid leukemia. Hematol Oncol Stem Cell Ther; 2010;3(1):42-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Megakaryocytic blast crisis at presentation in a pediatric patient with chronic myeloid leukemia.
  • Patients with chronic myeloid leukemia (CML) infrequently present in blast crisis (BC).
  • While most BC are of myeloid origin, megakaryocytic BC is rare, especially at the time of CML diagnosis.
  • We describe the first pediatric patient presenting with megakaryocytic leukemia and having BCR-ABL1 translocation as the single chromosomal abnormality.
  • Clinical features were more suggestive of CML in megakaryocytic blast crisis than Philadelphia chromosome positive de novo AML.
  • The patient was treated with AML-directed chemotherapy and imatinib mesylate followed by umbilical cord blood stem cell transplantation.
  • [MeSH-major] Blast Crisis / pathology. Leukemia, Megakaryoblastic, Acute / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Megakaryocytes / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Benzamides. Child. Cord Blood Stem Cell Transplantation. Diagnosis, Differential. Female. Humans. Imatinib Mesylate. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Remission Induction. Treatment Outcome


44. Porkka K, Koskenvesa P, Lundán T, Rimpiläinen J, Mustjoki S, Smykla R, Wild R, Luo R, Arnan M, Brethon B, Eccersley L, Hjorth-Hansen H, Höglund M, Klamova H, Knutsen H, Parikh S, Raffoux E, Gruber F, Brito-Babapulle F, Dombret H, Duarte RF, Elonen E, Paquette R, Zwaan CM, Lee FY: Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood; 2008 Aug 15;112(4):1005-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
  • Although imatinib, a BCR-ABL tyrosine kinase inhibitor, is used to treat acute Philadelphia chromosome-positive (Ph(+)) leukemia, it does not prevent central nervous system (CNS) relapses resulting from poor drug penetration through the blood-brain barrier.
  • Imatinib and dasa-tinib (a dual-specific SRC/BCR-ABL kinase inhibitor) were compared in a preclinical mouse model of intracranial Ph(+) leukemia.
  • Clinical dasatinib treatment in patients with CNS Ph(+) leukemia was assessed.
  • The drug also demonstrated substantial activity in 11 adult and pediatric patients with CNS Ph(+) leukemia.
  • [MeSH-major] Blood-Brain Barrier / metabolism. Central Nervous System Neoplasms / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Pyrimidines / administration & dosage. Pyrimidines / pharmacokinetics. Thiazoles / administration & dosage. Thiazoles / pharmacokinetics
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Child. Cytogenetic Analysis. Dasatinib. Disease Models, Animal. Drug Evaluation, Preclinical. Drug Monitoring. Female. Humans. Male. Mice. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Remission Induction. Spinal Puncture. Survival Rate. Treatment Outcome. Tumor Burden / drug effects

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18477770.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00108719/ NCT00110097
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrimidines; 0 / Thiazoles; RBZ1571X5H / Dasatinib
  •  go-up   go-down


45. Lee SJ, Joffe S, Artz AS, Champlin RE, Davies SM, Jagasia M, Kernan NA, Loberiza FR Jr, Soiffer RJ, Eapen M: Individual physician practice variation in hematopoietic cell transplantation. J Clin Oncol; 2008 May 1;26(13):2162-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: An international Internet-based survey of transplant physicians collected data on medical decisions made by adult and pediatric HCT physicians.
  • Pediatric and adult transplant physicians differed significantly in their management strategies for chronic myeloid leukemia, acute and chronic graft-versus-host disease, and choice of graft source for patients with aplastic anemia.
  • [MeSH-major] Anemia, Aplastic / surgery. Graft vs Host Disease / surgery. Hematopoietic Stem Cell Transplantation. Leukemia / surgery. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Lymphoma, Non-Hodgkin / surgery. Patient Selection. Practice Patterns, Physicians'
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blast Crisis / surgery. Decision Making. Female. Health Care Surveys. Health Services Accessibility. Healthcare Disparities. Humans. Immunosuppressive Agents / therapeutic use. Internet. Leukemia, Myeloid, Acute / surgery. Male. Middle Aged. Practice Guidelines as Topic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Quality of Health Care. Residence Characteristics. Surveys and Questionnaires. Transplantation Conditioning. Transplantation, Homologous


46. Lehrnbecher T, Bernig T, Hanisch M, Koehl U, Behl M, Reinhardt D, Creutzig U, Klingebiel T, Chanock SJ, Schwabe D: Common genetic variants in the interleukin-6 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia. Leukemia; 2005 Oct;19(10):1745-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common genetic variants in the interleukin-6 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia.
  • Infectious complications represent a substantial cause of morbidity and mortality in children undergoing therapy for acute myeloid leukemia (AML).
  • Since it has been shown that alterations in innate immune pathways contribute to the risk for serious infections, we analyzed well-characterized variants in innate immune genes (TNF, IL6, IL8, MPO, CHIT, FCGR2A, TLR2, and TLR4) to determine their possible contribution to infectious complications during therapy for pediatric AML.
  • The study population consisted of 168 North European Caucasian children enrolled on the clinical trial AML-BFM 93.
  • Our data suggest that variant alleles of both IL6 and CHIT could influence susceptibility to infection with Gram-negative bacteria in children undergoing therapy for AML.
  • [MeSH-major] Gram-Negative Bacterial Infections / etiology. Hexosaminidases / genetics. Interleukin-6 / genetics. Leukemia, Myeloid / genetics. Polymorphism, Genetic. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Alleles. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Clinical Trials as Topic. Female. Genetic Variation. Genotype. Gram-Negative Bacteria / isolation & purification. Humans. Infant. Infant, Newborn. Male

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16107886.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukin-6; EC 3.2.1.- / Hexosaminidases; EC 3.2.1.- / chitotriosidase
  •  go-up   go-down


47. Barrera M, Atenafu E, Andrews GS, Saunders F: Factors related to changes in cognitive, educational and visual motor integration in children who undergo hematopoietic stem cell transplant. J Pediatr Psychol; 2008 Jun;33(5):536-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Investigate cognitive, educational, and perceptual motor skills up to 2 years posttransplant of pediatric hematopoietic progenitor cell transplantation (HPCT) survivors and their correlates.
  • Full IQ and educational outcomes were positively related to child's age and mother's age.
  • CONCLUSIONS: Pediatric HPCT survivors do better cognitively than educationally.
  • Maternal age and depression, child's age, and time since diagnosis are critical factors for these outcomes.
  • [MeSH-major] Achievement. Hematopoietic Stem Cell Transplantation / psychology. Intelligence. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid, Acute / therapy. Neoplasms / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Psychomotor Performance
  • [MeSH-minor] Age Factors. Child. Combined Modality Therapy. Cranial Irradiation / adverse effects. Depression / psychology. Female. Follow-Up Studies. Humans. Male. Mathematics. Mothers / psychology. Prognosis. Reaction Time / radiation effects. Wechsler Scales


48. Brown P, Smith FO: Molecularly targeted therapies for pediatric acute myeloid leukemia: progress to date. Paediatr Drugs; 2008;10(2):85-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecularly targeted therapies for pediatric acute myeloid leukemia: progress to date.
  • While acute myeloid leukemia (AML) is significantly less common than acute lymphoblastic leukemia (ALL) in childhood, it is significantly more deadly with only half as many children likely to be cured with standard therapy.
  • In addition, the typical treatment for AML is among the most toxic of treatments for pediatric cancer; it includes intensive multiagent chemotherapy and, often, hematopoietic stem cell transplantation.
  • Given the poor prognosis of pediatric AML and the significant toxicity of standard AML therapy, novel therapies are needed.
  • Improved understanding of the molecular and cellular biology of leukemia has facilitated the development of molecularly targeted therapies.
  • In this article, we review progress to date with agents that are showing promise in the treatment of pediatric AML including targeted immunoconjugates, inhibitors of signaling molecules (e.g.
  • For the specific agents in each of these classes, we summarize the published preclinical data and the clinical trials that have been completed, are in progress, or are being planned for children with AML.
  • Finally, we discuss potential challenges to the success of molecularly targeted therapy including demonstrating adequate targeting of leukemia stem cells, developing synergistic and tolerable combinations of agents, and designing adequately powered clinical trials to test efficacy in molecularly defined subsets of patients.
  • [MeSH-major] Leukemia, Myeloid, Acute

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Oct 15;108(8):2764-9 [16809615.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6361-9 [16778214.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):565-9 [16261562.001]
  • [Cites] Leukemia. 2003 May;17 (5):995-7 [12750723.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1811-6 [1373089.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1277-84 [15735013.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):99-110 [12957285.001]
  • [Cites] Leuk Lymphoma. 2006 Feb;47(2):207-22 [16321850.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3262-70 [16857985.001]
  • [Cites] Blood. 2007 Feb 15;109 (4):1387-94 [17082323.001]
  • [Cites] Blood. 2001 Oct 15;98 (8):2301-7 [11588023.001]
  • [Cites] Leukemia. 1999 Jan;13(1):38-43 [10049058.001]
  • [Cites] Int J Hematol. 2005 Aug;82(2):100-7 [16146839.001]
  • [Cites] N Engl J Med. 2003 Mar 27;348(13):1201-14 [12660384.001]
  • [Cites] Blood. 1999 Mar 15;93(6):2043-56 [10068678.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1692-7 [12411300.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1183-8 [15886328.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Blood. 2007 May 15;109 (10 ):4168-70 [17227830.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2005-12 [7718872.001]
  • [Cites] Curr Hematol Rep. 2004 May;3(3):203-9 [15087069.001]
  • [Cites] Med Pediatr Oncol. 1999 Dec;33(6):525-9 [10573574.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1841-9 [15166029.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4222-4 [12010830.001]
  • [Cites] Blood. 2001 Jan 1;97(1):89-94 [11133746.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):837-41 [9041182.001]
  • [Cites] Blood. 1999 May 15;93(10):3302-8 [10233882.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Blood. 2004 May 15;103(10):3669-76 [14726387.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1516-22 [17332297.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3058-65 [15626743.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5165-73 [16951235.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2434-9 [11290608.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4276-84 [14962898.001]
  • [Cites] Blood. 1997 Jul 15;90(2):489-519 [9226149.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3654-61 [16912228.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3271-9 [16882711.001]
  • [Cites] Leukemia. 2003 Feb;17(2):350-8 [12592335.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7233-9 [11585760.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Jun;321(3):953-60 [17389244.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23 ):4816-22 [15570084.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1267-70 [15988530.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] Eur J Clin Invest. 2007 Jan;37(1):73-82 [17181570.001]
  • [Cites] Blood. 2003 Aug 1;102(3):972-80 [12702506.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1333-7 [9737679.001]
  • [Cites] Leukemia. 2003 Jan;17 (1):83-8 [12529664.001]
  • [Cites] Blood. 2005 Jul 15;106(2):673-80 [15797998.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2325-31 [14644997.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):811-4 [9486654.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3244-54 [11432892.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1466-73 [12689934.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16220-5 [12451177.001]
  • [Cites] Blood. 2005 Jul 1;106(1):345-52 [15774615.001]
  • [Cites] Blood. 2000 Jan 15;95(2):639-45 [10627474.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1995-9 [15187030.001]
  • [Cites] Cell Growth Differ. 1992 Jul;3(7):461-9 [1419908.001]
  • [Cites] Leukemia. 2002 May;16(5):813-9 [11986941.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2393-8 [12239147.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1145-50 [15126317.001]
  • [Cites] Science. 2002 Feb 8;295(5557):1079-82 [11834837.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S30-5 [16341238.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1368-76 [16761017.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3371-6 [15161691.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1442-52 [16116598.001]
  • [Cites] Adv Exp Med Biol. 2003;532:121-40 [12908554.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3361-9 [11369625.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1315-24 [16254147.001]
  • [Cites] Br J Haematol. 1991 Mar;77(3):323-7 [2012756.001]
  • [Cites] Leukemia. 1999 Dec;13(12):1932-42 [10602413.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3885-91 [12010785.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2527-34 [15550488.001]
  • [Cites] Leukemia. 1987 Oct;1(10):697-705 [3312833.001]
  • [Cites] Blood. 2001 Aug 15;98 (4):988-94 [11493443.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(5):707-21, discussion 722-4 [15010072.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2707-16 [16981007.001]
  • [Cites] Cell Cycle. 2006 Feb;5(3):271-3 [16397415.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1154-63 [15870183.001]
  • [Cites] Semin Hematol. 2004 Apr;41(2 Suppl 4):27-32 [15190513.001]
  • [Cites] Leukemia. 2004 Mar;18(3):375-84 [14737069.001]
  • [Cites] Blood. 2007 Jun 15;109 (12 ):5151-6 [17351110.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1089-96 [8562934.001]
  • [Cites] Blood. 2002 Jan 1;99(1):319-25 [11756187.001]
  • [Cites] Blood. 1993 Aug 1;82(3):792-9 [8338945.001]
  • [Cites] Lancet. 2007 Jul 28;370(9584):342-50 [17662883.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):815-8 [9486655.001]
  • (PMID = 18345718.001).
  • [ISSN] 1174-5878
  • [Journal-full-title] Paediatric drugs
  • [ISO-abbreviation] Paediatr Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA111728
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Histone Deacetylase Inhibitors; 0 / Proteasome Inhibitors; 0 / Protein Kinase Inhibitors; EC 2.5.1.29 / Farnesyltranstransferase; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Number-of-references] 92
  •  go-up   go-down


49. Bachas C, Schuurhuis GJ, Hollink IH, Kwidama ZJ, Goemans BF, Zwaan CM, van den Heuvel-Eibrink MM, de Bont ES, Reinhardt D, Creutzig U, de Haas V, Assaraf YG, Kaspers GJ, Cloos J: High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood; 2010 Oct 14;116(15):2752-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine.
  • Although virtually all pediatric patients with acute myeloid leukemia (AML) achieve a complete remission after initial induction therapy, 30%-40% of patients will encounter a relapse and have a dismal prognosis.
  • To determine relevance of established AML type I/II mutations that may serve as therapeutic targets, we assessed frequencies of these mutations and their persistence during disease progression in a large group (n = 69) of paired diagnosis and relapse pediatric AML specimens.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Mutation. Precision Medicine
  • [MeSH-minor] Adolescent. Base Sequence. Biomarkers, Tumor / genetics. Child. Child, Preschool. Cohort Studies. DNA Mutational Analysis. DNA Primers / genetics. DNA, Neoplasm / genetics. Female. Follow-Up Studies. Genes, Wilms Tumor. Genes, ras. Humans. Infant. Male. Prognosis. Recurrence. Time Factors. Treatment Outcome. fms-Like Tyrosine Kinase 3 / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2010 Oct 14;116(15):2622-3 [20947687.001]
  • (PMID = 20592250.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA Primers; 0 / DNA, Neoplasm; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


50. Hattori H, Matsuzaki A, Suminoe A, Koga Y, Tashiro K, Hara T: Identification of novel genes with prognostic value in childhood leukemia using cDNA microarray and quantitative RT-PCR. Pediatr Hematol Oncol; 2006 Mar;23(2):115-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of novel genes with prognostic value in childhood leukemia using cDNA microarray and quantitative RT-PCR.
  • The aim of this study was to identify genes distinctively expressed or suppressed in childhood leukemia with different prognoses, using cDNA microarray and quantitative reverse transcription-polymerase chain reaction (RT-PCR).
  • The expression levels of the selected genes by cDNA microarray were quantified in primary leukemic blasts from 44 patients (acute lymphoblastic leukemia, 28; acute myelogenous leukemia (AML), 13; transient myeloproliferative disorder, 3).
  • The expression levels of CDKN2C, CRADD, and IGFBP-2 genes were significantly associated with the event-free survival of the patients in AML.
  • The present results suggest that a combination of cDNA microarray and quantitative RT-PCR may be useful to identify novel genes with prognostic value in childhood AML.
  • [MeSH-major] Genes, Neoplasm. Leukemia / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / genetics. Adolescent. CRADD Signaling Adaptor Protein. Caspase 2. Child. Child, Preschool. Cyclin-Dependent Kinase Inhibitor p18 / genetics. Cysteine Endopeptidases / genetics. Female. Gene Expression Profiling. Humans. Infant. Infant, Newborn. Insulin-Like Growth Factor Binding Protein 2 / genetics. Male. Neoplasm Proteins / genetics. Oligonucleotide Array Sequence Analysis. Prognosis. Protein-Serine-Threonine Kinases / genetics. Receptor-Interacting Protein Serine-Threonine Kinases. Reverse Transcriptase Polymerase Chain Reaction. Tumor Necrosis Factor Receptor-Associated Peptides and Proteins / genetics

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16651240.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / CDKN2C protein, human; 0 / CRADD Signaling Adaptor Protein; 0 / CRADD protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p18; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Neoplasm Proteins; 0 / Tumor Necrosis Factor Receptor-Associated Peptides and Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / RIPK1 protein, human; EC 2.7.11.1 / Receptor-Interacting Protein Serine-Threonine Kinases; EC 3.4.22.- / CASP2 protein, human; EC 3.4.22.- / Caspase 2; EC 3.4.22.- / Cysteine Endopeptidases
  •  go-up   go-down


51. Lee DH, Kwon YJ, Lim J, Kim Y, Han K, Chung NG, Jeong DC, Cho B, Kim HK: Comparable outcomes of HLA-matched unrelated and HLA-identical sibling donor bone marrow transplantation for childhood acute myeloid leukemia in first remission. Pediatr Transplant; 2009 Mar;13(2):210-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparable outcomes of HLA-matched unrelated and HLA-identical sibling donor bone marrow transplantation for childhood acute myeloid leukemia in first remission.
  • We retrospectively investigated the outcomes of HLA-matched unrelated BMT (MU-BMT, n = 13) and HLA-identical sibling donor BMT (MS-BMT, n = 17) for childhood AML in CR1 between June 2002 and August 2005.
  • The cumulative incidence of grade II-IV acute GVHD and any chronic GVHD at three yr was not different between MS-BMT and MU-BMT.
  • The outcome of HLA-matched unrelated BMT is comparable to that of HLA-identical sibling BMT for childhood AML in CR1.
  • HLA-matched unrelated BMT may be recommended for patients who have AML in CR1 without an HLA-matched sibling donor.
  • [MeSH-major] Bone Marrow Transplantation / methods. HLA Antigens / metabolism. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Blood Platelets / metabolism. Child. Child, Preschool. Female. Humans. Living Donors. Male. Neutrophils / metabolism. Remission Induction. Retrospective Studies. Siblings. Treatment Outcome


52. Mizushima Y, Taki T, Shimada A, Yui Y, Hiraumi Y, Matsubara H, Watanabe M, Watanabe K, Kamitsuji Y, Hayashi Y, Tsukimoto I, Kobayashi R, Horibe K, Tawa A, Nakahata T, Adachi S: Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group. Int J Hematol; 2010 Jun;91(5):831-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group.
  • High BAALC (brain and acute leukemia, cytoplasmic) gene expression may indicate an adverse prognosis for adults who have acute myeloid leukemia (AML) and a normal karyotype, but its prognostic significance for pediatric AML cases is unclear.
  • Newly diagnosed AML patients with normal karyotype who were treated by the Japanese Childhood AML Cooperative Treatment Protocol AML 99 were analyzed in terms of their BAALC expression levels (n = 29), BAALC isoforms (n = 29), and CEBPA mutations (n = 49).
  • Thus, 1-5-6-8 isoform expression may be associated with an adverse prognosis in pediatric AML with normal karyotype.
  • [MeSH-major] Asian Continental Ancestry Group / genetics. CCAAT-Enhancer-Binding Proteins. Gene Expression Regulation, Leukemic. Leukemia, Myeloid, Acute / diagnosis. Mutation. Neoplasm Proteins
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Karyotyping. Male. Prognosis. Protein Isoforms / genetics


53. Kobayashi R, Kaneda M, Sato T, Ichikawa M, Suzuki D, Ariga T: The clinical feature of invasive fungal infection in pediatric patients with hematologic and malignant diseases: a 10-year analysis at a single institution at Japan. J Pediatr Hematol Oncol; 2008 Dec;30(12):886-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical feature of invasive fungal infection in pediatric patients with hematologic and malignant diseases: a 10-year analysis at a single institution at Japan.
  • The clinical feature of IFI after chemotherapy and SCT were analyzed in 334 pediatric patients treated at Hokkaido University Hospital from 1997 to 2006.
  • Fifty-nine pediatric patients died in our institution over the 10-year period of the study and IFI was the direct cause of death in 18.6% (11/59) of the patients.
  • Univariate analysis showed that age at diagnosis older than 10 years, relapse of original disease, long-term administration of broad-spectrum antibiotics, and acute myelogenous leukemia (AML) were the risk factors for IFI.
  • AML was most strongly associated using a multivariate analysis.
  • The prognosis of IFI has been expected poor; therefore, prevention of this condition, especially for older patients with AML, would be important.
  • [MeSH-minor] Adolescent. Adult. Antifungal Agents / therapeutic use. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Japan / epidemiology. Male. Risk Factors. Stem Cell Transplantation. Survival Rate. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131772.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


54. Mehta PA, Alonzo TA, Gerbing RB, Elliott JS, Wilke TA, Kennedy RJ, Ross JA, Perentesis JP, Lange BJ, Davies SM, Children's Oncology Group: XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report. Blood; 2006 Jan 1;107(1):39-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report.
  • Polymorphisms in XPD, a member of the nucleotide excision repair pathway, have been associated with development of treatment-related acute myeloid leukemia (AML) and with poor outcome of AML in elderly patients.
  • We hypothesized that XPD Lys751Gln polymorphism may play a role in causation of AML in children and, as shown in adults, may affect the outcome of childhood AML therapy.
  • Genotyping of 456 children treated for de novo AML was performed at XPD exon 23.
  • Gene frequencies in AML patients and healthy controls were similar.
  • There were no significant differences in overall survival (P = .82), event-free survival (P = .78), treatment-related mortality (P = .43), or relapse rate (RR) (P = .92) between patients with XPD751AA versus 751AC versus 751CC genotypes, in contrast to reports in adult AML.
  • These data, representing the only data in pediatric AML, suggest that XPD genotype does not affect the etiology or outcome of childhood AML.
  • [MeSH-major] Leukemia, Myeloid / genetics. Polymorphism, Single Nucleotide. Xeroderma Pigmentosum Group D Protein / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Case-Control Studies. Child. Child, Preschool. Female. Gene Frequency. Genetic Testing. Genotype. Humans. Infant. Infant, Newborn. Male. Mutation, Missense. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Childhood.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16150943.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human
  •  go-up   go-down


55. Kaspers GJ, Creutzig U: Pediatric acute myeloid leukemia: international progress and future directions. Leukemia; 2005 Dec;19(12):2025-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric acute myeloid leukemia: international progress and future directions.
  • [MeSH-major] Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Child. Forecasting. Humans. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304569.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Editorial; Review
  • [Publication-country] England
  • [Number-of-references] 30
  •  go-up   go-down


56. Hiçsönmez G: A novel approach to treatment in childhood acute myeloblastic leukemia and myelodysplastic syndrome with high-dose methylprednisolone as a differentiation- and apoptosis-inducing agent of myeloid leukemic cells. Turk J Haematol; 2010 Mar 5;27(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel approach to treatment in childhood acute myeloblastic leukemia and myelodysplastic syndrome with high-dose methylprednisolone as a differentiation- and apoptosis-inducing agent of myeloid leukemic cells.
  • [Transliterated title] Çocukluk yaşı akut myeloblastik lösemi ve myelodisplastik sendromunda myeloid lösemik hücrelerde farklılaşma ve apoptosisi sağlayan yüksek doz metilprednizolon ile yeni bir tedavi yaklaşımı.
  • Differentiation-inducing therapy with all-trans retinoic acid significantly improved the outcome in children with acute promyelocytic leukemia (APL).
  • Based on the experimental studies in mice, we have shown that short-course high-dose methylprednisolone (HDMP) treatment can induce terminal differentiation of leukemic cells in children with various subtypes of acute myeloblastic leukemia (AML-M1,-M2,-M3,-M4,-M7).
  • It has also been shown to induce apoptosis of myeloid leukemic cells with or without differentiation.
  • Administration of HDMP as a single agent resulted in a rapid clinical improvement, a marked decrease in blast cells in both peripheral blood and bone marrow and dramatic decreases in the size of extramedullary leukemic mass in children with AML and myelodysplastic syndrome (MDS).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27265790.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


57. Walter RB, Alonzo TA, Gerbing RB, Ho PA, Smith FO, Raimondi SC, Hirsch BA, Gamis AS, Franklin JL, Hurwitz CA, Loken MR, Meshinchi S: High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group. J Clin Oncol; 2010 Jun 10;28(17):2831-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group.
  • PURPOSE: To evaluate the prognostic significance of the integrin cell adhesion molecule very late antigen-4 (VLA-4) in acute myeloid leukemia (AML).
  • Subgroup analyses indicated that the prognostic role of VLA-4 expression was most prominent in patients with standard-risk AML, in whom low VLA-4 expression was associated with inferior DFS (34% +/- 16% v 69% +/- 14% for high expression; P = .011) and higher RR (61% +/- 16% v 26% +/- 14% for high expression; P = .009).
  • CONCLUSION: High VLA-4 expression is associated with better clinical outcome in pediatric AML and is an independent predictor of relapse that may refine our abilities to stratify patients without identifiable cytogenetic or molecular risk factors.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Apr 1;97(7):2121-9 [11264180.001]
  • [Cites] Cell. 2002 Sep 20;110(6):673-87 [12297042.001]
  • [Cites] Br J Haematol. 2003 Aug;122(4):579-89 [12899713.001]
  • [Cites] Nat Med. 2003 Sep;9(9):1158-65 [12897778.001]
  • [Cites] Blood. 1993 Nov 15;82(10):3125-32 [7693037.001]
  • [Cites] Leukemia. 1996 Apr;10(4):682-6 [8618447.001]
  • [Cites] Blood. 2009 Oct 1;114(14):3008-17 [19636064.001]
  • [Cites] Nat Rev Immunol. 2007 Sep;7(9):678-89 [17717539.001]
  • [Cites] Leuk Res. 2008 Jun;32(6):845-6 [18023867.001]
  • [Cites] Blood. 2009 Jan 22;113(4):866-74 [18927435.001]
  • [Cites] Annu Rev Immunol. 2009;27:339-62 [19302044.001]
  • [Cites] Leuk Res. 2009 Jun;33(6):764-8 [19042019.001]
  • [Cites] Genome Biol. 2007;8(5):215 [17543136.001]
  • (PMID = 20421533.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U24 CA114766; United States / NCI NIH HHS / CA / K23 CA137161; United States / NCI NIH HHS / CA / R01 CA114563; United States / NCI NIH HHS / CA / U10 CA098543
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrin alpha4beta1
  • [Other-IDs] NLM/ PMC2903318
  •  go-up   go-down


58. Alioglu B, Avci Z, Ozcay F, Arda S, Ozbek N: Neutropenic enterocolitis in children with acute leukemia or aplastic anemia. Int J Hematol; 2007 Nov;86(4):364-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutropenic enterocolitis in children with acute leukemia or aplastic anemia.
  • Neutropenic enterocolitis (NE) and acute appendicitis are life-threatening conditions that develop in children with severe or prolonged neutropenia secondary to acute leukemia and lymphoma.
  • The medical records of 118 patients who were treated for acute lymphoblastic leukemia (69 patients), acute myelogenous leukemia (22 patients), or aplastic anemia (27 patients) between 1997 and 2006 in our hospital pediatric hematology department were examined retrospectively.
  • Conservative treatment was favored for all patients, but 1 patient with acute appendicitis underwent surgery.
  • NE and acute appendicitis should always be considered in the differential diagnosis of abdominal pain.
  • [MeSH-major] Anemia, Aplastic / pathology. Enterocolitis, Neutropenic / complications. Enterocolitis, Neutropenic / pathology. Leukemia, Myeloid, Acute / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Male. Tomography, X-Ray Computed


59. Ho PA, Zeng R, Alonzo TA, Gerbing RB, Miller KL, Pollard JA, Stirewalt DL, Heerema NA, Raimondi SC, Hirsch B, Franklin JL, Lange B, Meshinchi S: Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood; 2010 Aug 05;116(5):702-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
  • Recent studies of WT1 mutations in acute myeloid leukemia (AML) mostly report an association with unfavorable clinical outcome.
  • We screened 842 patients treated on 3 consecutive pediatric AML trials for WT1 zinc-finger mutations.
  • In current risk stratification schemes incorporating cytogenetics and FLT3/ITD status, the presence of WT1 mutations has no independent prognostic significance in predicting outcome in pediatric AML.
  • [MeSH-major] Genes, Wilms Tumor. Leukemia, Myeloid / genetics. Mutation
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Cohort Studies. DNA Mutational Analysis. DNA, Neoplasm / genetics. Exons / genetics. Female. Humans. Infant. Infant, Newborn. Kaplan-Meier Estimate. Karyotyping. Male. Prevalence. Prognosis. Proportional Hazards Models. Retrospective Studies. Tandem Repeat Sequences / genetics. Treatment Outcome. Young Adult. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Jan 1;97(1):89-94 [11133746.001]
  • [Cites] Leukemia. 2007 May;21(5):868-76 [17361230.001]
  • [Cites] Br J Haematol. 2004 Jun;125(5):590-600 [15147374.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4140-6 [15483024.001]
  • [Cites] Leukemia. 1992 May;6(5):405-9 [1317488.001]
  • [Cites] Hum Mol Genet. 1994 Sep;3(9):1633-7 [7833922.001]
  • [Cites] Hum Mol Genet. 1995 Mar;4(3):351-8 [7795587.001]
  • [Cites] Biochemistry. 1996 Sep 17;35(37):12070-6 [8810912.001]
  • [Cites] Hum Mutat. 1997;9(3):209-25 [9090524.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9152-4 [16230371.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3654-61 [16912228.001]
  • [Cites] Curr Opin Hematol. 2007 Mar;14(2):106-14 [17255787.001]
  • [Cites] Leukemia. 2007 Mar;21(3):550-1; author reply 552 [17205055.001]
  • [Cites] Blood. 2007 Aug 1;110(3):979-85 [17440048.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1044-53 [18000167.001]
  • [Cites] Leukemia. 2008 May;22(5):915-31 [18288131.001]
  • [Cites] Semin Oncol. 2008 Aug;35(4):346-55 [18692685.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5429-35 [18591546.001]
  • [Cites] Blood. 2009 May 7;113(19):4505-11 [19221039.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5951-60 [19171881.001]
  • [Cites] Blood. 2009 Jun 25;113(26):6558-66 [19304957.001]
  • [Cites] Cancer. 2009 Aug 15;115(16):3719-27 [19536888.001]
  • [Cites] Leukemia. 2009 Aug;23(8):1472-9 [19322206.001]
  • [Cites] Pediatr Blood Cancer. 2009 Dec;53(6):1136-9 [19618455.001]
  • [Cites] Blood. 2010 Mar 25;115(12):2372-9 [20056794.001]
  • [Cites] Gene. 2001 Aug 8;273(2):141-61 [11595161.001]
  • (PMID = 20413658.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00002798/ NCT00070174
  • [Grant] United States / NCI NIH HHS / CA / R01 CA114563; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / R21CA10262-01; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Other-IDs] NLM/ PMC2918327
  •  go-up   go-down


60. Mulrooney DA, Dover DC, Li S, Yasui Y, Ness KK, Mertens AC, Neglia JP, Sklar CA, Robison LL, Davies SM, Childhood Cancer Survivor Study: Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study. Cancer; 2008 May 1;112(9):2071-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study.
  • BACKGROUND: Limited data exist on the comprehensive assessment of late medical and social effects experienced by survivors of childhood and young adult acute myeloid leukemia (AML).
  • METHODS: This analysis included 272 5-year AML survivors who participated in the Childhood Cancer Survivor Study (CCSS).
  • The cumulative incidence of recurrent AML was 6.6% at 10 years (95% CI, 3.7%-9.6%) and 8.6% at 20 years (95% CI, 5.1%-12.1%).
  • CONCLUSIONS: Long-term survival from childhood AML > or =5-years after diagnosis was favorable.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Childhood.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18327823.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / K12 RR023247; United States / NCI NIH HHS / CA / U24 CA055727; United States / NCRR NIH HHS / RR / 1 K12 RR 023247; United States / NCI NIH HHS / CA / U24 CA 55727
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Robison LL; Hudson M; Armstrong G; Perkins J; O'Leary M; Friedman D; Pendergrass T; Greffe B; Odom L; Ruccione K; Mulvihill J; Ginsberg J; Meadows A; Tersak J; Ritchey A; Blatt J; Reaman G; Packer R; Davies S; Bhatia S; Qualman S; Hammond S; Termuhlen A; Ruymann F; Diller L; Grier H; Li F; Meacham L; Mertens A; Leisenring W; Potter J; Greenberg M; Nathan PC; Boice J; Rodriguez V; Smithson WA; Gilchrist G; Sklar C; Oeffinger K; Finklestein J; Anderson B; Inskip P; Vik TA; Weetman R; Green DM; Hayashi R; Vietti T; Marina N; Donaldson SS; Link MP; Dreyer Z; Whelan K; Sande J; Berkow R; Yasui Y; Casallis J; Zeltzer L; Goldsby R; Ablin A; Hutchinson R; Neglia J; Deapen D; Breslow N; Bowers D; Tomlinson G; Buchanan GR; Strong L; Stovall M
  •  go-up   go-down


61. Schultz KA, Chen L, Chen Z, Zeltzer LK, Nicholson HS, Neglia JP: Health and risk behaviors in survivors of childhood acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer; 2010 Jul 15;55(1):157-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health and risk behaviors in survivors of childhood acute myeloid leukemia: a report from the Children's Oncology Group.
  • BACKGROUND: Survivors of childhood acute myeloid leukemia (AML) face increased risks of chronic disease and secondary malignancies.
  • PROCEDURES: Participants were diagnosed with AML at <21 years of age and survived > or =5 years following diagnosis.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Childhood.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Nurs Forum. 1999 Oct;26(9):1475-86 [11064879.001]
  • [Cites] Drug Alcohol Depend. 2008 Nov 1;98(1-2):13-23 [18585871.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] Med Pediatr Oncol. 2001 Jul;37(1):42-6 [11466722.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):189-96 [12525509.001]
  • [Cites] JAMA. 2003 Sep 24;290(12):1583-92 [14506117.001]
  • [Cites] Ann Intern Med. 2004 Apr 6;140(7):557-68 [15068985.001]
  • [Cites] Semin Oncol. 1982 Mar;9(1):34-51 [6176027.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1448-57 [8336184.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):127-35 [8270968.001]
  • [Cites] J Natl Cancer Inst. 1994 Jan 19;86(2):131-7 [8271296.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2367-77 [7964952.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4979-89 [8652810.001]
  • [Cites] J Natl Cancer Inst. 1998 Feb 4;90(3):219-25 [9462679.001]
  • [Cites] Ann Epidemiol. 2005 Mar;15(3):202-6 [15723765.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6516-23 [16116148.001]
  • [Cites] Semin Hematol. 2006 Jan;43(1):42-52 [16412788.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):476-83 [16421424.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):565-9 [16261562.001]
  • [Cites] Prev Med. 2006 Jun;42(6):435-42 [16626797.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1303-12 [16894525.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2007 Nov 9;56(44):1157-61 [17989644.001]
  • [Cites] Cancer. 2008 May 1;112(9):2071-9 [18327823.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • (PMID = 20232426.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA055727; United States / NCI NIH HHS / CA / U10 CA98413; United States / NCI NIH HHS / CA / 5U10CA78960; United States / NCI NIH HHS / CA / U24 CA55727; United States / NCI NIH HHS / CA / U10 CA007306-39; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543-08; None / None / / U10 CA098543-08; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA078960-04; United States / NCI NIH HHS / CA / CA007306-39; United States / NCI NIH HHS / CA / U10 CA098413-08; None / None / / U10 CA098413-08; United States / NCI NIH HHS / CA / U10 CA98543; United States / NCI NIH HHS / CA / 5U10 CA07306; United States / NCI NIH HHS / CA / R01 CA078960-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS166508; NLM/ PMC3152207
  •  go-up   go-down


62. Belson M, Kingsley B, Holmes A: Risk factors for acute leukemia in children: a review. Environ Health Perspect; 2007 Jan;115(1):138-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for acute leukemia in children: a review.
  • Although overall incidence is rare, leukemia is the most common type of childhood cancer.
  • Within this population, acute lymphocytic leukemia (ALL) occurs approximately five times more frequently than acute myelogenous leukemia (AML) and accounts for approximately 78% of all childhood leukemia diagnoses.
  • Epidemiologic studies of acute leukemias in children have examined possible risk factors, including genetic, infectious, and environmental, in an attempt to determine etiology.
  • Only one environmental risk factor (ionizing radiation) has been significantly linked to ALL or AML.
  • Most environmental risk factors have been found to be weakly and inconsistently associated with either form of acute childhood leukemia.
  • Our review focuses on the demographics of childhood leukemia and the risk factors that have been associated with the development of childhood ALL or AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology
  • [MeSH-minor] Child. Communicable Diseases / complications. Environmental Exposure. Genetic Predisposition to Disease. Humans. Risk Factors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1989 Jul 15;49(14):4030-7 [2736544.001]
  • [Cites] BMJ. 1990 Feb 17;300(6722):423-9 [2107892.001]
  • [Cites] Am J Hum Genet. 1990 Jun;46(6):1041-52 [2160192.001]
  • [Cites] Pediatr Hematol Oncol. 1987;4(1):63-72 [3152913.001]
  • [Cites] Br J Cancer. 1990 Dec;62(6):1008-14 [2257204.001]
  • [Cites] Environ Health Perspect. 1990 Aug;88:325-37 [2272330.001]
  • [Cites] Med J Aust. 1991 Apr 1;154(7):483-7 [2005848.001]
  • [Cites] BMJ. 1991 Mar 23;302(6778):681-7 [2021741.001]
  • [Cites] BMJ. 1991 Mar 23;302(6778):687-92 [2021742.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1351-5 [1873786.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):549-54 [1911197.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):406-12 [11161408.001]
  • [Cites] Int J Epidemiol. 2001 Feb;30(1):125-9 [11171872.001]
  • [Cites] Am J Epidemiol. 2001 Mar 15;153(6):615-7 [11257071.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2542-6 [11289128.001]
  • [Cites] Am J Public Health. 2001 Apr;91(4):564-7 [11291366.001]
  • [Cites] Cancer Causes Control. 2001 Aug;12(6):483-90 [11519756.001]
  • [Cites] Paediatr Perinat Epidemiol. 2001 Oct;15(4):338-45 [11703681.001]
  • [Cites] Radiat Res. 2001 Dec;156(6):718-23 [11741495.001]
  • [Cites] Environ Health Perspect. 1991 Aug;94:5-7 [1954939.001]
  • [Cites] Eur J Cancer. 1992;29A(1):87-95 [1445751.001]
  • [Cites] BMJ. 1993 Jan 9;306(6870):89-94 [8435648.001]
  • [Cites] Leukemia. 1993 Mar;7(3):349-60 [8445941.001]
  • [Cites] BMJ. 1993 Mar 6;306(6878):615-21 [8461811.001]
  • [Cites] BMJ. 1993 May 1;306(6886):1153-8 [8499814.001]
  • [Cites] Leukemia. 1993 Aug;7 Suppl 2:S146-7 [8361221.001]
  • [Cites] BMJ. 1993 Oct 16;307(6910):959-66 [8241906.001]
  • [Cites] Med Pediatr Oncol. 1994;22(2):78-83 [8259105.001]
  • [Cites] Nature. 1994 Feb 24;367(6465):678-80 [8107860.001]
  • [Cites] BMJ. 1994 Jul 16;309(6948):154-7 [8044093.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Sep;3(6):457-60 [8000294.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):1-5 [7819022.001]
  • [Cites] Am J Public Health. 1995 Feb;85(2):249-52 [7856787.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Dec;3(8):645-53 [7881337.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2186-95 [7697611.001]
  • [Cites] Epidemiol Rev. 1994;16(2):243-72 [7713179.001]
  • [Cites] Environ Health Perspect. 1995 Jun;103(6):550-4 [7556005.001]
  • [Cites] Eur J Cancer Prev. 1995 Sep;4 Suppl 1:3-107 [7496333.001]
  • [Cites] J Natl Cancer Inst. 1996 Jan 3;88(1):24-31 [8847721.001]
  • [Cites] Ann Epidemiol. 1995 Sep;5(5):354-9 [8653207.001]
  • [Cites] Environ Health Perspect. 1995 Sep;103 Suppl 6:177-84 [8549470.001]
  • [Cites] Epidemiology. 1999 Sep;10(5):481-7 [10468419.001]
  • [Cites] JAMA. 2003 Oct 15;290(15):2001-7 [14559953.001]
  • [Cites] Curr Opin Pediatr. 2004 Feb;16(1):9-14 [14758108.001]
  • [Cites] Environ Mol Mutagen. 2004;43(2):100-9 [14991750.001]
  • [Cites] Cancer Detect Prev. 2004;28(2):83-7 [15068830.001]
  • [Cites] Cancer Res. 1967 Dec;27(12):2420-3 [4230121.001]
  • [Cites] J Natl Cancer Inst. 1968 May;40(5):1079-85 [5648133.001]
  • [Cites] Nature. 1971 Apr 9;230(5293):370-3 [4927726.001]
  • [Cites] Lancet. 1971 Apr 3;1(7701):699-701 [4101637.001]
  • [Cites] Science. 1973 Dec 28;182(4119):1355-6 [4586464.001]
  • [Cites] J Med Genet. 1977 Apr;14(2):81-90 [856959.001]
  • [Cites] Cancer Res. 1978 Mar;38(3):485-93 [203382.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1675-8 [6929216.001]
  • [Cites] J Pediatr. 1981 Sep;99(3):425-8 [7264801.001]
  • [Cites] Am J Ind Med. 1981;2(3):217-45 [7345926.001]
  • [Cites] J Occup Med. 1984 Sep;26(9):679-82 [6207280.001]
  • [Cites] Leuk Res. 1985;9(6):817-23 [3159943.001]
  • [Cites] Am J Epidemiol. 1985 Feb;121(2):216-24 [3860001.001]
  • [Cites] Nature. 1987 Jan 22-28;325(6102):355-7 [3808031.001]
  • [Cites] Br J Cancer. 1987 Feb;55(2):179-90 [3814487.001]
  • [Cites] J Natl Cancer Inst. 1987 Jul;79(1):39-46 [3474448.001]
  • [Cites] Prog Clin Biol Res. 1987;246:19-32 [2958880.001]
  • [Cites] Am J Epidemiol. 1988 Apr;127(4):713-25 [3354538.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1428-37 [11821358.001]
  • [Cites] BMJ. 2002 Feb 2;324(7332):283-7 [11823363.001]
  • [Cites] Lancet. 2002 Feb 2;359(9304):431-4 [11844534.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Feb;11(2):177-85 [11867505.001]
  • [Cites] Environ Health Perspect. 2002 Mar;110(3):319-24 [11882484.001]
  • [Cites] Rev Environ Health. 2001 Jul-Sep;16(4):263-79 [12041882.001]
  • [Cites] Lancet Oncol. 2002 May;3(5):269-79 [12067803.001]
  • [Cites] Environ Health Perspect. 2002 Sep;110(9):955-60 [12204832.001]
  • [Cites] Br J Cancer. 2002 Sep 23;87(7):740-5 [12232757.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15101-6 [12415113.001]
  • [Cites] Pharmacogenetics. 2002 Nov;12(8):655-8 [12439226.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4 [9391133.001]
  • [Cites] Br J Cancer. 1998 Mar;77(5):842-9 [9514068.001]
  • [Cites] Epidemiology. 1998 May;9(3):234-45 [9583414.001]
  • [Cites] Leukemia. 1998 May;12(5):645-51 [9593260.001]
  • [Cites] Environ Health Perspect. 1998 Jun;106 Suppl 3:893-908 [9646054.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):119-24 [9662261.001]
  • [Cites] Radiat Environ Biophys. 1998 Jul;37(2):87-93 [9728740.001]
  • [Cites] Radiat Res. 1998 Nov;150(5 Suppl):S30-41 [9806607.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1380-8 [10189146.001]
  • [Cites] Teratology. 1999 Apr;59(4):227-33 [10331524.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 16;91(12):1051-8 [10379968.001]
  • [Cites] Int J Radiat Biol. 1999 Jul;75(7):801-10 [10489891.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Sep;8(9):783-91 [10498397.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Sep;8(9):793-9 [10498398.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):549-53 [10507784.001]
  • [Cites] N Engl J Med. 1955 Jul 21;253(3):88-90 [14394332.001]
  • [Cites] Lancet. 1956 Sep 1;271(6940):447 [13358242.001]
  • [Cites] Arch Intern Med. 1961 Jul;108:86-90 [13720079.001]
  • [Cites] N Engl J Med. 1965 Apr 29;272:882-7 [14274439.001]
  • [Cites] N Engl J Med. 1959 Sep 17;261:585-9 [14425443.001]
  • [Cites] J Epidemiol Community Health. 2005 Feb;59(2):101-5 [15650139.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):651-5 [15767345.001]
  • [Cites] Environ Health. 2004;3(1):12 [15533260.001]
  • [Cites] Occup Environ Med. 2006 Feb;63(2):131-4 [16421392.001]
  • [Cites] Environ Health Perspect. 2003 Apr;111(4):663-8 [12676632.001]
  • [Cites] Hematol Oncol. 2003 Jun;21(2):51-5 [12802809.001]
  • [Cites] Environ Health Perspect. 2003 Jun;111(7):962-70 [12782499.001]
  • [Cites] Epidemiology. 2003 Jul;14(4):437-41 [12843769.001]
  • [Cites] Epidemiology. 2003 Sep;14(5):569-77 [14501272.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2321-33 [12791663.001]
  • [Cites] Lancet. 1988 Sep 17;2(8612):665-9 [2901525.001]
  • [Cites] Lancet. 1988 Dec 10;2(8624):1323-7 [2904050.001]
  • [Cites] Cancer. 1989 May 15;63(10):1904-11 [2649219.001]
  • [Cites] Radiat Res. 1996 May;145(5):595-601 [8619025.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):1006-12 [8611419.001]
  • [Cites] Med Pediatr Oncol Suppl. 1996;1:29-34 [8643045.001]
  • [Cites] Nature. 1996 Jul 25;382(6589):352-3 [8684463.001]
  • [Cites] Int J Cancer. 1996 Jul 29;67(3):343-52 [8707407.001]
  • [Cites] Cancer. 1995 Apr 1;75(7):1718-27 [8826933.001]
  • [Cites] Cancer Causes Control. 1996 Nov;7(6):581-90 [8932918.001]
  • [Cites] J Natl Cancer Inst. 1997 Feb 5;89(3):238-44 [9017004.001]
  • [Cites] Br J Cancer. 1997;75(3):457-63 [9020498.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1):3-16 [9045302.001]
  • [Cites] Occup Environ Med. 1996 Nov;53(11):773-81 [9038803.001]
  • [Cites] Br J Radiol. 1997 Feb;70:130-9 [9135438.001]
  • [Cites] Ann Epidemiol. 1997 Apr;7(3):172-9 [9141639.001]
  • [Cites] Cancer. 1997 May 15;79(10):2045-51 [9149034.001]
  • [Cites] Nature. 1997 May 15;387(6630):246 [9153387.001]
  • [Cites] Occup Environ Med. 1997 Mar;54(3):152-66 [9155776.001]
  • [Cites] N Engl J Med. 1997 Jul 3;337(1):1-7 [9203424.001]
  • [Cites] J Natl Cancer Inst. 1997 Jul 2;89(13):939-47 [9214673.001]
  • [Cites] Pediatr Clin North Am. 1997 Aug;44(4):831-46 [9286287.001]
  • [Cites] Environ Health Perspect. 1997 Oct;105(10):1068-77 [9349828.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1765-72 [10528028.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):813-23 [10673523.001]
  • [Cites] Curr Opin Oncol. 2000 Jan;12(1):3-12 [10687723.001]
  • [Cites] Am J Epidemiol. 2000 Mar 1;151(5):512-5 [10707920.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):692-8 [10944614.001]
  • [Cites] Am J Epidemiol. 2000 Sep 1;152(5):480-6 [10981463.001]
  • [Cites] Epidemiology. 2000 Nov;11(6):624-34 [11055621.001]
  • [CommentIn] Environ Health Perspect. 2007 Aug;115(8):A395-6 [17687418.001]
  • [CommentIn] Environ Health Perspect. 2007 Aug;115(8):A395 [17687419.001]
  • [ErratumIn] Environ Health Perspect. 2010 Sep;118(9):A380
  • (PMID = 17366834.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 145
  • [Other-IDs] NLM/ PMC1817663
  •  go-up   go-down


63. Cavalier M, Shmalo JA, Yu M, Billings SD, Abonour R, Nelson RP Jr: Skin cancer after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transplant; 2006 Jun;37(12):1103-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients had myelodysplasia or acute myelogenous leukemia prior to transplantation.
  • [MeSH-major] Carcinoma, Basal Cell. Carcinoma, Squamous Cell. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Melanoma. Myelodysplastic Syndromes. Neoplasms, Second Primary. Skin Neoplasms. Transplantation Conditioning. Transplantation, Homologous


64. Yeh TC, Liu HC, Wang LY, Chen SH, Lin WY, Liang DC: The development of a novel protocol for the treatment of de novo childhood acute myeloid leukemia in a single institution in Taiwan. J Pediatr Hematol Oncol; 2007 Dec;29(12):826-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The development of a novel protocol for the treatment of de novo childhood acute myeloid leukemia in a single institution in Taiwan.
  • From November 1, 1995 to July 31, 2004, 49 children with de novo acute myeloid leukemia (AML) were treated at our institution.
  • In total, 48 patients with de novo AML were enrolled in this study.
  • Forty-two patients with AML other than acute promyelocytic leukemia (non-APL) were treated consecutively with 2 novel protocols: Mackay Memorial Hospital (MMH)-AML-96, designed as a pilot phase, and Taiwan Pediatric Oncology Group (TPOG)-AML-97A, on the basis of MMH-AML-96 with minor modifications.
  • The 5-year overall survival was 64%+/-6.9% (SE), and the 5-year event-free survival was 60%+/-7.1%; for non-APL AML, the rates were 62%+/-7.5% and 59%+/-7.6%; for APL, 83+/-15.2 and 67+/-19.3%.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Child. Child, Preschool. Drug Administration Schedule. Female. Humans. Infant. Male. Survival Rate. Survivors. Taiwan


65. Kong Y, Yoshida S, Saito Y, Doi T, Nagatoshi Y, Fukata M, Saito N, Yang SM, Iwamoto C, Okamura J, Liu KY, Huang XJ, Lu DP, Shultz LD, Harada M, Ishikawa F: CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia; 2008 Jun;22(6):1207-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL.
  • In human acute myelogenous leukemia (AML), the leukemia stem cells (LSCs) have been phenotypically restricted within the CD34+CD38- fraction.
  • To understand the origin of malignant cells in primary human B-precursor acute lymphocytic leukemia (B-ALL), we established a novel in vivo xenotransplantation model.
  • Purified CD34+CD38+CD19+, CD34+CD38-CD19+ and CD34+CD38-CD19- bone marrow (BM) or peripheral blood (PB) cells from three pediatric B-ALL patients were intravenously injected into sublethally irradiated newborn NOD/SCID/IL2rgamma(null) mice.
  • The identification of CD34+CD38+CD19+ self-renewing B-ALL cells proposes a hierarchy of leukemia-initiating cells (LICs) distinct from that of AML.
  • [MeSH-major] Antigens, CD19 / metabolism. Antigens, CD34 / metabolism. Antigens, CD38 / metabolism. Hematopoietic Stem Cells / pathology. Neoplastic Stem Cells / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Animals. Animals, Newborn. Cell Differentiation. Cell Lineage. Child. Flow Cytometry. Graft Survival. Humans. Immunophenotyping. Infant. Mice. Mice, Inbred NOD. Mice, SCID. Transplantation, Heterologous. Tumor Cells, Cultured. Whole-Body Irradiation

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - NOD.Cg-Prkdc<scid> Il2rg<tm1Wjl>/SzJ (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18418410.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD34; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


66. Gregory J, Feusner J: Acute promyelocytic leukemia in childhood. Curr Oncol Rep; 2009 Nov;11(6):439-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promyelocytic leukemia in childhood.
  • Acute promyelocytic leukemia (APL) is a relatively rare form of acute myelogenous leukemia (AML).
  • In the United States, APL in children constitutes only 5% to 10% of AML.
  • Molecularly, the disease is characterized by a fusion protein, promyelocytic leukemia (PML)-retinoic acid receptor (RAR)-alpha that results from a balanced reciprocal translocation between the PML gene on chromosome 15 and the RAR-alpha (RARA) gene on chromosome 17.
  • Advances in the treatment of APL have taken this form of AML from a disease with significant morbidity and mortality to one with an excellent outcome.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use. Tretinoin / therapeutic use
  • [MeSH-minor] Anthracyclines / therapeutic use. Child. Child, Preschool. Chromosomes, Human, Pair 15. Chromosomes, Human, Pair 17. Humans. Prognosis. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1992 Nov 1;80(9):2176-81 [1421389.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1587-90 [15356649.001]
  • [Cites] Blood. 2009 Feb 26;113(9):1875-91 [18812465.001]
  • [Cites] Blood. 1998 Aug 1;92(3):784-9 [9680345.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):78-85 [9440726.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3315-24 [10552940.001]
  • [Cites] Blood. 1992 Feb 1;79(3):543-53 [1732003.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3015-21 [10556184.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7632-40 [16234524.001]
  • [Cites] Blood. 2005 Jul 15;106(2):447-53 [15677559.001]
  • [Cites] Blood. 1992 Apr 15;79(8):1916-9 [1562718.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1600-4 [12886249.001]
  • [Cites] Ann Intern Med. 1985 Oct;103(4):620-5 [3862359.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3768-76 [16105978.001]
  • [Cites] Leukemia. 2000 Aug;14(8):1371-7 [10942231.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1237-43 [14576047.001]
  • [Cites] N Engl J Med. 1996 May 30;334(22):1428-34 [8618581.001]
  • [Cites] Pediatr Blood Cancer. 2008 Aug;51(2):210-5 [18428427.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35 [15044693.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):504-10 [19075265.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2627-32 [16352810.001]
  • [Cites] Blood. 2010 Oct 28;116(17):3171-9 [20644121.001]
  • [Cites] Blood. 1990 Nov 1;76(9):1710-7 [2224120.001]
  • [Cites] Eur J Cancer Prev. 2006 Aug;15(4):367-70 [16835508.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1994 Nov;16(4):384-6 [7978063.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1192-200 [10438706.001]
  • [Cites] J Biol Regul Homeost Agents. 1999 Oct-Dec;13(4):195-200 [10703942.001]
  • [Cites] Am J Med. 1984 May;76(5):827-41 [6586073.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5703-10 [17116939.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):133-5 [18293388.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1341-8 [9801394.001]
  • [Cites] Pediatr Blood Cancer. 2009 Jan;52(1):11-3 [18816805.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4131-43 [10361110.001]
  • [Cites] Pediatr Blood Cancer. 2008 Oct;51(4):521-4 [18493994.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1247-53 [10942364.001]
  • [Cites] Ann Hematol. 2002 Sep;81(9):504-7 [12373350.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):824-30 [18541203.001]
  • [Cites] Leukemia. 1997 Jul;11(7):921-8 [9204969.001]
  • [Cites] Br J Haematol. 2005 Jul;130(2):196-202 [16029447.001]
  • [Cites] Leukemia. 2007 Mar;21(3):446-52 [17205057.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]
  • [Cites] Ann Hematol. 2001 Jul;80(7):417-22 [11529468.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1404-12 [15084614.001]
  • (PMID = 19840521.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  • [Number-of-references] 47
  •  go-up   go-down


67. Liu CF, Liu GL, Zhang LP, Cheng YF, Lu AD, Tian KG, Liu YR, Qin YZ: [Clinical significance of detection of AML1/ETO fusion transcripts in childhood AML using real-time quantitative reverse transcription polymerase chain reaction]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb;13(1):76-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of detection of AML1/ETO fusion transcripts in childhood AML using real-time quantitative reverse transcription polymerase chain reaction].
  • Fourteen AML1/ETO positive children out of 52 AML children were selected.
  • It is concluded that real-time RT-PCR is a suitable approach for quantifying AML1/ETO transcripts in monitoring of AML patients with t(8;21) during/after chemotherapy and provides data of diagnostic relevance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15748440.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


68. Burke MJ, Willert J, Desai S, Kadota R: The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era. Pediatr Blood Cancer; 2009 Dec;53(6):992-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era.
  • PROCEDURE: Thirty-two pediatric centers across the United States and Canada were surveyed regarding current treatment practices for Ph+ acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML).
  • CONCLUSIONS: Although a treatment consensus did not exist based on the results of this small survey, current treatment practices for pediatric Ph+ ALL and CML appear to favor allogeneic-HCT when a MSD is available.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / therapeutic use

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621426.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


69. Ghosh I, Thulkar S, Arora R, Bakhshi S: Multifocal osteomyelitis as a presenting manifestation of childhood acute myeloid leukemia. J Pediatr Hematol Oncol; 2009 Jan;31(1):75-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal osteomyelitis as a presenting manifestation of childhood acute myeloid leukemia.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Osteomyelitis / diagnosis


70. Wang J, Ouyang J, Zhou R, Chen B, Yang Y: Autologous hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission: a meta-analysis of randomized trials. Acta Haematol; 2010;124(2):61-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission: a meta-analysis of randomized trials.
  • METHODS: A meta-analysis evaluating autologous SCT versus further chemotherapy or no treatment for acute myeloid leukemia (AML) in first complete remission (CR1) was completed.
  • Four studies were in pediatric patients and 9 were in adults.
  • For adults, AML in CR1 compared with non-SCT, lower relapse and higher transplantation-related mortality were associated with autologous SCT, a significant disease-free survival benefit of autologous SCT was documented, and there was no difference in overall survival when studies were pooled.
  • For pediatric AML in CR1, there were no differences in relapse, transplantation-related mortality, disease-free survival and overall survival.
  • CONCLUSION: Our results support the conclusion that autologous SCT should not be considered as the first-line post-remission therapy for AML patients in CR1.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / mortality. Hematopoietic Stem Cell Transplantation / statistics & numerical data. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy


71. Cazzaniga G, Dell'Oro MG, Mecucci C, Giarin E, Masetti R, Rossi V, Locatelli F, Martelli MF, Basso G, Pession A, Biondi A, Falini B: Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood; 2005 Aug 15;106(4):1419-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype.
  • Nucleophosmin (NPM) is a nucleocytoplasmic shuttling protein involved in leukemia-associated chromosomal translocations, and it regulates the alternate reading frame (ARF)-p53 tumor-suppressor pathway.
  • Cytoplasmic NPM was detected in 35% of adult patients with primary non-French-American-British (FAB) classification M3 acute myeloid leukemia (AML), associated mainly with normal karyotype.
  • We evaluated the prevalence of the NPM1 gene mutation in non-M3 childhood AML patients enrolled in the ongoing Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP-AML02) protocol in Italy.
  • Thus, the NPM1 mutation is a frequent abnormality in AML patients without known genetic marker; the mutation may represent a new target to monitor minimal residual disease in AML and a potential candidate for alternative and targeted treatments.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Mutation. Nuclear Proteins / genetics
  • [MeSH-minor] Adolescent. Age Factors. Base Sequence. Child. Child, Preschool. Cytoplasm / chemistry. DNA Mutational Analysis. Exons. Female. Humans. Karyotyping. Male. Molecular Sequence Data


72. Xie C, Edwards H, Xu X, Zhou H, Buck SA, Stout ML, Yu Q, Rubnitz JE, Matherly LH, Taub JW, Ge Y: Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res; 2010 Nov 15;16(22):5499-510
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia.
  • PURPOSE: To determine the possibility of synergistic antileukemic activity and the underlying molecular mechanisms associated with cytarabine combined with valproic acid (VPA; a histone deacetylase inhibitor and a Food and Drug Administration-licensed drug for treating both children and adults with epilepsy) in pediatric acute myeloid leukemia (AML).
  • EXPERIMENTAL DESIGN: The type and extent of antileukemic interactions between cytarabine and VPA in clinically relevant pediatric AML cell lines and diagnostic blasts from children with AML were determined by MTT assays and standard isobologram analyses.
  • RESULTS: We showed synergistic antileukemic activities between cytarabine and VPA in four pediatric AML cell lines and nine diagnostic AML blast samples. t(8;21) AML blasts were significantly more sensitive to VPA and showed far greater sensitivities to combined cytarabine and VPA than non-t(8;21) AML cases.
  • CONCLUSIONS: Our results establish global synergistic antileukemic activity of combined VPA and cytarabine in pediatric AML and provide compelling evidence to support the use of VPA in the treatment of children with this deadly disease.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Blood. 2008 Mar 1;111(5):2505-15 [18299451.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Sep;298(3):865-72 [11504778.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4500-10 [18628465.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2744-52 [19638627.001]
  • [Cites] Mol Cell Biol. 2009 Dec;29(23):6149-69 [19805519.001]
  • [Cites] EMBO J. 2001 Dec 17;20(24):6969-78 [11742974.001]
  • [Cites] Leuk Res. 2002 May;26(5):495-502 [11916526.001]
  • [Cites] Leukemia. 2003 Jan;17(1):120-4 [12529668.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):425-9 [14706334.001]
  • [Cites] Leukemia. 2004 Jul;18(7):1246-51 [15116123.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1266-9 [15155466.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):264-79 [15491285.001]
  • [Cites] Adv Cancer Res. 1998;72:197-233 [9338077.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1393-400 [10438727.001]
  • [Cites] Nat Med. 2005 Jan;11(1):71-6 [15619634.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):226-31 [15687366.001]
  • [Cites] Leuk Res. 2005 Jul;29(7):739-48 [15927669.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3923-31 [15897550.001]
  • [Cites] Leuk Res. 2005 Nov;29(11):1335-42 [15936818.001]
  • [Cites] Trends Mol Med. 2005 Oct;11(10):442-4 [16150641.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16090-5 [16243973.001]
  • [Cites] Blood. 2006 Jan 1;107(1):241-9 [16141349.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):112-9 [16323176.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1174-82 [16675713.001]
  • [Cites] Mol Cancer Res. 2006 Aug;4(8):563-73 [16877702.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8903-11 [16951208.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):769-84 [16955068.001]
  • [Cites] Pharmacol Rev. 2006 Sep;58(3):621-81 [16968952.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3271-9 [16882711.001]
  • [Cites] Seizure. 2006 Dec;15(8):630-2 [17070075.001]
  • [Cites] Leukemia. 2007 Feb;21(2):248-52 [17122863.001]
  • [Cites] Oncologist. 2007 Mar;12(3):341-55 [17405900.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1979-85 [17513804.001]
  • [Cites] Blood. 2007 Jul 1;110(1):267-77 [17356134.001]
  • [Cites] Curr Drug Targets. 2007 Jun;8(6):727-37 [17584028.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2302-8 [17596541.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1519-32 [18024401.001]
  • [Cites] Curr Biol. 2000 Jul 27-Aug 10;10(15):886-95 [10959836.001]
  • [Cites] Cancer Treat Rev. 2008 May;34(3):206-22 [18226465.001]
  • (PMID = 20889917.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA120772-01A2; United States / NCI NIH HHS / CA / R01 CA120772; United States / NCI NIH HHS / CA / CA120772; United States / NCI NIH HHS / CA / R01 CA120772-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 614OI1Z5WI / Valproic Acid; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 9
  • [Other-IDs] NLM/ NIHMS238223; NLM/ PMC3018695
  •  go-up   go-down


73. Ozyurek E, Arda S, Ozkiraz S, Alioglu B, Arikan U, Ozbek N: Febrile neutropenia as the presenting sign of appendicitis in an adolescent with acute myelogenous leukemia. Pediatr Hematol Oncol; 2006 Apr-May;23(3):269-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Febrile neutropenia as the presenting sign of appendicitis in an adolescent with acute myelogenous leukemia.
  • The diagnosis and management of a surgical abdomen in patients with acute leukemia is quite difficult because of the complications and treatment of disease itself.
  • A 13-year-old boy with acute myelogenous leukemia developed 2 episodes of febrile neutropenia during induction therapy.
  • The case illustrates that fever may be the first manifestation of appendicitis in a child with acute myelogenous leukaemia who is neutropenic.
  • [MeSH-major] Abdomen, Acute / etiology. Appendicitis / diagnosis. Enterocolitis, Necrotizing / diagnosis. Fever / etiology. Leukemia, Monocytic, Acute / complications. Neutropenia / complications

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Appendicitis.
  • MedlinePlus Health Information. consumer health - Fever.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. AMIKACIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16517543.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Cephalosporins; 62XCK0G93T / Ornidazole; 7XU7A7DROE / Amphotericin B; 807PW4VQE3 / cefepime; 84319SGC3C / Amikacin
  •  go-up   go-down


74. Styczynski J: Drug resistance in childhood acute myeloid leukemia. Curr Pharm Biotechnol; 2007 Apr;8(2):59-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug resistance in childhood acute myeloid leukemia.
  • Therapy results in childhood AML differ from those of ALL.
  • The development of drug resistance is the limiting factor in the therapy of AML.
  • Different problems of drug resistance in childhood AML, with emphasis to age and in comparison to adult AML are presented.
  • Taking into account both children and adults, it seems that age is adversely related to therapy outcome in AML, and the percentage of patients with favorable cytogenetics decreases with age; however, age is positively correlated with multi-drug resistance and the proportion of patients with unfavorable cytogenetics.
  • AML is considered a stem cell disease.
  • Cellular drug resistance in AML cells seems to be similar throughout all other age groups, however the higher the age, the worse the outcome.
  • In childhood AML, no drug is more effective in comparison to ALL, and cellular drug resistance is partially related to chromosomal abnormalities.
  • Pediatric AML is equally resistant as adult AML.
  • Pediatric and adult AML, respectively, are possibly equally drug resistant on initial diagnosis and at relapse.
  • In contrast to ALL, the prognostic value of in vitro drug resistance in childhood AML has not been well documented yet.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / epidemiology. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control


75. Nebral K, König M, Schmidt HH, Lutz D, Sperr WR, Kalwak K, Brugger S, Dworzak MN, Haas OA, Strehl S: Screening for NUP98 rearrangements in hematopoietic malignancies by fluorescence in situ hybridization. Haematologica; 2005 Jun;90(6):746-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVES: The aim of this study was to determine the incidence of rearrangements of NUP98 (the gene coding for nucleoporin 98kDa protein) in childhood acute myeloid leukemia (AML) and selected patients with 11p13-15 rearrangements.
  • DESIGN AND METHODS: Screening of 59 consecutive patients enrolled in the Austrian AML-BFM93 clinical trial was performed by dual-color FISH.
  • RESULTS: Among the 59 AML patients, one NUP98-NSD1 positive case (1.7%) was detected.
  • INTERPRETATION AND CONCLUSIONS: The observed frequency of 1.7% confirmed the low incidence of NUP98 rearrangements in childhood AML.
  • [MeSH-major] Chromosome Aberrations. Hematologic Neoplasms / diagnosis. Hematologic Neoplasms / genetics. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / genetics. Nuclear Pore Complex Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Amino Acid Sequence. Base Sequence. Child. Child, Preschool. Chromosome Inversion. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Molecular Sequence Data. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951287.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Nuclear Pore Complex Proteins; 0 / nuclear pore complex protein 98
  •  go-up   go-down


76. Wheeler AD, Tobias JD: Nesiritide in a pediatric oncology patient with renal insufficiency and myocardial dysfunction following septic shock. Pediatr Hematol Oncol; 2005 Jun;22(4):323-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nesiritide in a pediatric oncology patient with renal insufficiency and myocardial dysfunction following septic shock.
  • The authors report on a 17-year-old with acute myelogenous leukemia who was admitted to the Pediatric ICU for treatment of septic shock, respiratory failure, myocardial dysfunction, and renal insufficiency.
  • The end-organ effects of nesiritide, previous reports regarding its use in the pediatric population, and its potential applications in the ICU setting are discussed.
  • [MeSH-major] Cardiomyopathies / drug therapy. Leukemia, Myeloid, Acute / complications. Natriuretic Peptide, Brain / therapeutic use. Renal Insufficiency / drug therapy. Shock, Septic / complications

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16020120.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


77. Castagnola E, Rossi MR, Cesaro S, Livadiotti S, Giacchino M, Zanazzo G, Fioredda F, Beretta C, Ciocchello F, Carli M, Putti MC, Pansini V, Berger M, Licciardello M, Farina S, Caviglia I, Haupt R: Incidence of bacteremias and invasive mycoses in children with acute non-lymphoblastic leukemia: results from a multi-center Italian study. Pediatr Blood Cancer; 2010 Dec 1;55(6):1103-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of bacteremias and invasive mycoses in children with acute non-lymphoblastic leukemia: results from a multi-center Italian study.
  • BACKGROUND: Data on the epidemiology of bacteremias and invasive fungal diseases (IFD) in children with acute myeloid leukemia (AML) are scarce.
  • DESIGN AND METHODS: In a multi-center, retrospective study, we analyzed proportion, rate per 1,000 person-days at risk, and cumulative risk of bacteremias and IFD in children with AML.
  • RESULTS: Between January 1998 and December 2005, 240 children were treated for AML at 8 Italian Centers, for a total of 521 treatment courses and 63,232 person-days at risk.
  • The epidemiology of bacteremias and IFD was different during front-line therapy for M3 as compared to other types of AML, but the differences were not statistically significant.
  • CONCLUSIONS: Severe infectious complications are frequent during the treatment of pediatric AML, especially during relapse treatment, and bacteremias are more frequent than IFD.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bacteremia / etiology. Leukemia, Myeloid, Acute / microbiology. Mycoses / etiology
  • [MeSH-minor] Child. Female. Follow-Up Studies. Humans. Incidence. Italy. Male. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / microbiology. Retrospective Studies


78. Cloos J, Goemans BF, Hess CJ, van Oostveen JW, Waisfisz Q, Corthals S, de Lange D, Boeckx N, Hählen K, Reinhardt D, Creutzig U, Schuurhuis GJ, Zwaan ChM, Kaspers GJ: Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia; 2006 Jul;20(7):1217-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples.
  • In acute myeloid leukemia (AML), activating mutations in the fms-like tyrosine kinase 3 (FLT3) gene predict poor prognosis.
  • We determined FLT3 internal tandem duplications (FLT3/ITD) and D835 point mutations in paired initial and relapse samples from 80 pediatric and adult AML patients.
  • One D835 point mutation was found in an initial pediatric AML sample.
  • [MeSH-major] Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / genetics. Point Mutation. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] Adolescent. Adult. Female. Genetic Markers. Genetic Predisposition to Disease / epidemiology. Humans. Leukemia, Erythroblastic, Acute / genetics. Leukemia, Megakaryoblastic, Acute / genetics. Leukemia, Monocytic, Acute / genetics. Leukemia, Myelomonocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / genetics. Male. Neoplasm, Residual / epidemiology. Neoplasm, Residual / genetics. Prognosis. Recurrence. Risk Factors. Tandem Repeat Sequences

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16642044.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


79. Burjanivova T, Madzo J, Muzikova K, Meyer C, Schneider B, Votava F, Marschalek R, Stary J, Trka J, Zuna J: Prenatal origin of childhood AML occurs less frequently than in childhood ALL. BMC Cancer; 2006;6:100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prenatal origin of childhood AML occurs less frequently than in childhood ALL.
  • BACKGROUND: While there is enough convincing evidence in childhood acute lymphoblastic leukemia (ALL), the data on the pre-natal origin in childhood acute myeloid leukemia (AML) are less comprehensive.
  • Our study aimed to screen Guthrie cards (neonatal blood spots) of non-infant childhood AML and ALL patients for the presence of their respective leukemic markers.
  • In AML patients (n = 13, age 1-14 years) PML/RARalpha (n = 4), CBFbeta/MYH11 (n = 3), AML1/ETO (n = 2), MLL/AF6 (n = 1), MLL/AF9 (n = 1) and MLL/AF10 (n = 1) fusion genes and/or internal tandem duplication of FLT3 gene (FLT3/ITD) (n = 2) were used as clonotypic markers.
  • We did not find patient-specific molecular markers in any patient with AML.
  • CONCLUSION: In the largest cohort examined so far we used identical approach for the backtracking of non-infant childhood ALL and AML.
  • Our data suggest that either the prenatal origin of AML is less frequent or the load of pre-leukemic cells is significantly lower at birth in AML compared to ALL cases.
  • [MeSH-major] Biomarkers, Tumor / blood. DNA, Neoplasm / blood. Fetal Blood / chemistry. Gene Rearrangement, B-Lymphocyte. Gene Rearrangement, T-Lymphocyte. Leukemia, Myeloid / embryology. Oncogene Proteins, Fusion / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / embryology
  • [MeSH-minor] Bone Marrow Cells / chemistry. Child. Child, Preschool. Clone Cells / chemistry. Cohort Studies. Core Binding Factor Alpha 2 Subunit / blood. Core Binding Factor Alpha 2 Subunit / genetics. Female. Gene Duplication. Humans. Infant. Infant, Newborn. Male. Myeloid-Lymphoid Leukemia Protein / blood. Myeloid-Lymphoid Leukemia Protein / genetics. Neonatal Screening. Neoplasm Proteins / blood. Neoplasm Proteins / genetics. Polymerase Chain Reaction. Tandem Repeat Sequences. fms-Like Tyrosine Kinase 3 / blood. fms-Like Tyrosine Kinase 3 / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2003 Jul;122(1):24-9 [12823342.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):449-54 [15626757.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2321-33 [12791663.001]
  • [Cites] Lancet. 1999 Oct 30;354(9189):1499-503 [10551495.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3707-16 [10572083.001]
  • [Cites] Blood. 2000 Jul 1;96(1):264-8 [10891460.001]
  • [Cites] Blood. 2001 Jan 1;97(1):89-94 [11133746.001]
  • [Cites] Blood. 2001 Jul 15;98(2):478-82 [11435320.001]
  • [Cites] Blood. 2001 Oct 1;98(7):2272-4 [11568017.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2992-6 [11929791.001]
  • [Cites] Blood. 2002 May 15;99(10):3801-5 [11986239.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2387-92 [12239146.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2393-8 [12239147.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15101-6 [12415113.001]
  • [Cites] Br J Cancer. 2002 Oct 21;87(9):994-9 [12434291.001]
  • [Cites] Genes Chromosomes Cancer. 2003 May;37(1):36-43 [12661004.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4640-1 [12756163.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Aug;37(4):406-11 [12800152.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2202-6 [12931229.001]
  • [Cites] Leuk Lymphoma. 2003 Dec;44(12):2099-102 [14959854.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Apr;39(4):335-40 [14978794.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] Nucleic Acids Res. 1995 Sep 25;23(18):3788-9 [7479012.001]
  • [Cites] Blood. 1997 Jan 1;89(1):281-5 [8978302.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4 [9391133.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):6413-8 [9600980.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 May-Jun;20(3):264-7 [9628441.001]
  • [Cites] Leukemia. 1999 Jan;13(1):110-8 [10049045.001]
  • [Cites] Blood. 1999 May 1;93(9):3074-80 [10216104.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4079-85 [10361104.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1057-62 [10419898.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1667-9 [12886258.001]
  • (PMID = 16630339.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Biomarkers, Tumor; 0 / CBFbeta-MYH11 fusion protein; 0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA, Neoplasm; 0 / MLL-AF10 fusion protein, human; 0 / MLL-AF6 fusion protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Other-IDs] NLM/ PMC1463004
  •  go-up   go-down


80. Manola KN: Cytogenetics of pediatric acute myeloid leukemia. Eur J Haematol; 2009 Nov;83(5):391-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetics of pediatric acute myeloid leukemia.
  • Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease accounting for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients.
  • This article focuses on the significance of cytogenetic analysis in pediatric AML supporting the importance of cytogenetic analysis in the pathogenesis, diagnosis, prognosis, follow-up and treatment selection in childhood AML.
  • Furthermore, it discusses the association of specific chromosome rearrangements with prenatal exposure to carcinogenic agents or therapeutic agents and highlights the ongoing and future research on pediatric AML in the evolving field of Cytogenetics.
  • [MeSH-major] Cytogenetics / methods. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563518.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens, Environmental
  • [Number-of-references] 123
  •  go-up   go-down


81. Zhang H, Luo XQ, Zhang P, Huang LB, Zheng YS, Wu J, Zhou H, Qu LH, Xu L, Chen YQ: MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One; 2009;4(11):e7826
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia.
  • BACKGROUND: Recent reports have indicated that microRNAs (miRNAs) play a critical role in malignancies, and regulations in the progress of adult leukemia.
  • The role of miRNAs in pediatric leukemia still needs to be established.
  • The purpose of this study was to investigate the aberrantly expressed miRNAs in pediatric acute leukemia and demonstrate miRNA patterns that are pediatric-specific and prognostic parameter-associated.
  • METHODOLOGY/PRINCIPAL FINDINGS: A total of 111 pediatric bone marrow samples, including 99 patients and 12 normal donors, were enrolled in this study.
  • Of those samples, 36 patients and 7 normal samples were used as a test cohort for the evaluation of miRNA profiling; 63 pediatric patients and 5 normal donors were used as a validation cohort to confirm the miRNA differential expression.
  • Pediatric ALL- and AML-specific microRNA expression patterns were identified in this study.
  • The most highly expressed miRNAs in pediatric ALL were miR-34a, miR-128a, miR-128b, and miR-146a, while the highly expressed miRNAs in pediatric AML were miR-100, miR-125b, miR-335, miR-146a, and miR-99a, which are significantly different from those reported for adult CLL and AML. miR-125b and miR-126 may serve as favorable prognosticators for M3 and M2 patients, respectively.
  • CONCLUSIONS/SIGNIFICANCE: There are existing pediatric-associated and prognostic parameter-associated miRNAs that are independent of cell lineage and could provide therapeutic direction for individual risk-adapted therapy for pediatric leukemia patients.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Leukemia / diagnosis. Leukemia / pathology. MicroRNAs
  • [MeSH-minor] Child. Child, Preschool. Cohort Studies. Female. Gene Expression Profiling. Gene Expression Regulation. Humans. Infant. Male. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Risk

  • MedlinePlus Health Information. consumer health - Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2003 Apr 4;113(1):25-36 [12679032.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):438-42 [12600936.001]
  • [Cites] J Pediatr (Rio J). 2003 Mar-Apr;79(2):149-58 [14502336.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Feb;39(2):167-9 [14695998.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Genes Dev. 2004 Mar 1;18(5):504-11 [15014042.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):769-73 [15685193.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] Nature. 2005 Mar 17;434(7031):338-45 [15735639.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1768-71 [16251533.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):167-73 [16616063.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7390-4 [16885332.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19971-6 [18056805.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2825-32 [18089852.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3183-9 [18187662.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3945-50 [18308931.001]
  • [Cites] Blood. 2008 May 15;111(10):5078-85 [18337557.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15535-40 [18832181.001]
  • [Cites] J Exp Med. 2008 Oct 27;205(11):2499-506 [18936236.001]
  • [Cites] J Clin Oncol. 2008 Nov 1;26(31):5078-87 [18809607.001]
  • [Cites] Leukemia. 2009 Feb;23(2):313-22 [18923441.001]
  • [Cites] Dev Biol. 1999 Dec 15;216(2):671-80 [10642801.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):179-81 [12525506.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • (PMID = 19915715.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2773830
  •  go-up   go-down


82. Evrard AS, Hémon D, Billon S, Laurier D, Jougla E, Tirmarche M, Clavel J: Childhood leukemia incidence and exposure to indoor radon, terrestrial and cosmic gamma radiation. Health Phys; 2006 Jun;90(6):569-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood leukemia incidence and exposure to indoor radon, terrestrial and cosmic gamma radiation.
  • This study was undertaken to evaluate the ecological association between terrestrial and cosmic gamma radiation, indoor radon, and acute leukemia incidence among children under 15 y of age.
  • From 1990 to 2001, 5,330 cases of acute leukemia were registered by the French National Registry of Childhood Leukemia and Lymphoma.
  • There was no evidence of an ecological association between terrestrial gamma dose (range: 0.22-0.90 mSv y) or total gamma dose (range: 0.49-1.28 mSv y) and childhood acute leukemia incidence, for acute myeloid leukemia (AML) or for acute lymphoblastic leukemia (ALL), in univariate or multivariate regression analyses including indoor radon.
  • A significant positive association between indoor radon (range: 22-262 Bq m) and AML incidence among children was observed and remained significant in multivariate regression analyses including either terrestrial gamma dose [SIR per 100 Bq m = 1.29 (1.09-1.53)] or total gamma dose [SIR per 100 Bq m = 1.29 (1.09-1.53)].
  • The study showed no ecological association between terrestrial gamma radiation and childhood leukemia for the range of variation in gamma dose rates observed in France.
  • The moderate ecological association between childhood AML incidence and indoor radon does not appear to be confounded by terrestrial gamma dose.
  • [MeSH-major] Air Pollution, Indoor / analysis. Cosmic Radiation. Environmental Exposure / statistics & numerical data. Gamma Rays. Leukemia, Radiation-Induced / epidemiology. Radon / analysis. Risk Assessment / methods
  • [MeSH-minor] Body Burden. Child. Child, Preschool. Confounding Factors (Epidemiology). Female. France / epidemiology. Humans. Incidence. Male. Radiation Dosage. Registries. Relative Biological Effectiveness. Risk Factors

  • MedlinePlus Health Information. consumer health - Indoor Air Pollution.
  • MedlinePlus Health Information. consumer health - Radon.
  • Hazardous Substances Data Bank. RADON, RADIOACTIVE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16691105.001).
  • [ISSN] 0017-9078
  • [Journal-full-title] Health physics
  • [ISO-abbreviation] Health Phys
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q74S4N8N1G / Radon
  •  go-up   go-down


83. Rubnitz JE, Razzouk BI, Lensing S, Pounds S, Pui CH, Ribeiro RC: Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer; 2007 Jan 1;109(1):157-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia.
  • BACKGROUND: Outcome after recurrence of childhood acute myeloid leukemia (AML) is poor.
  • We performed this study to identify prognostic factors for recurrence and for survival after recurrence of AML.
  • METHODS: The clinical characteristics, biological features, treatment modalities, and outcomes of children with de novo AML who were enrolled on 3 consecutive clinical protocols from 1987 to 2002 at St. Jude Children's Research Hospital were studied.
  • CONCLUSIONS: Survival after recurrence was poor in children with AML.
  • Novel therapies are urgently needed to prevent or to treat recurring AML.
  • [MeSH-major] Leukemia, Myeloid / mortality
  • [MeSH-minor] Acute Disease. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Multivariate Analysis. Prognosis. Recurrence. Sex Factors. Stem Cell Transplantation. Survival Rate. Time Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Childhood.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 17133407.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA-21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


84. van der Velden VH, van der Sluijs-Geling A, Gibson BE, te Marvelde JG, Hoogeveen PG, Hop WC, Wheatley K, Bierings MB, Schuurhuis GJ, de Graaf SS, van Wering ER, van Dongen JJ: Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia; 2010 Sep;24(9):1599-606
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol.
  • Analysis of minimal residual disease (MRD) in childhood acute myeloid leukemia (AML) may predict for clinical outcome.
  • MRD levels were assessed by flowcytometric immunophenotyping in 94 children with AML enrolled into a single trial (United Kingdom Medical Research Council AML12 and similar Dutch Childhood Oncology Group ANLL97).
  • In conclusion, flowcytometric MRD detection is possible in children with AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Neoplasm, Residual / diagnosis
  • [MeSH-minor] Child. Clinical Protocols. Flow Cytometry. Humans. Immunophenotyping. Probability. Prognosis. RNA, Messenger / genetics. Recurrence

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20668473.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300133
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


85. Pellier I, Leboucher B, Rachieru P, Ifrah N, Rialland X: Flushing out of cerebrospinal fluid as a therapy for acute cerebellar dysfunction caused by high dose of cytosine arabinoside: a case report. J Pediatr Hematol Oncol; 2006 Dec;28(12):837-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flushing out of cerebrospinal fluid as a therapy for acute cerebellar dysfunction caused by high dose of cytosine arabinoside: a case report.
  • High dose of cytosine arabinoside is usually used in treatment of acute myelogenous leukemia.
  • Here we report 1 case of a child who developed neurologic toxicity and rapidly improved after flushing out of cerebral spinal fluid, suggesting it could be treatment in the acute phase of toxicity.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Cerebellar Diseases / chemically induced. Cerebellar Diseases / therapy. Cerebrospinal Fluid. Cytarabine / adverse effects. Leukemia, Myeloid, Acute / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cerebellar Disorders.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Hematol Oncol. 2007 Apr;29(4):274 [17414574.001]
  • (PMID = 17164656.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


91. Stasevich I, Utskevich R, Kustanovich A, Litvinko N, Savitskaya T, Chernyavskaya S, Saharova O, Aleinikova O: Translocation (10;11)(p12;q23) in childhood acute myeloid leukemia: incidence and complex mechanism. Cancer Genet Cytogenet; 2006 Sep;169(2):114-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation (10;11)(p12;q23) in childhood acute myeloid leukemia: incidence and complex mechanism.
  • This translocation represented 28% of all cases of childhood AML treated at our center in 2004, and 63% of AML with rearrangements of 11q23.
  • The median event-free survival of patients was 8.1 months, and we conclude that the t(10;11)(p12;q23) is associated with unfavorable prognosis in childhood acute myeloid leukemia.
  • [MeSH-major] Chromosomes, Human, Pair 10. Chromosomes, Human, Pair 11. Leukemia, Myeloid / genetics. Translocation, Genetic
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Chromosome Banding. Female. Humans. In Situ Hybridization, Fluorescence. Infant. Karyotyping. Male. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Childhood.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16938568.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


92. Petridou E, Mantzoros CS, Dessypris N, Dikalioti SK, Trichopoulos D: Adiponectin in relation to childhood myeloblastic leukaemia. Br J Cancer; 2006 Jan 16;94(1):156-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adiponectin in relation to childhood myeloblastic leukaemia.
  • Adiponectin, an adipocyte-specific secretory protein known to induce apoptosis, has been reported to be inversely related to breast and endometrial cancers and recently found to inhibit proliferation of myeloid but not lymphoid cell lines.
  • We hypothesised that adiponectin may be inversely associated with acute myeloblastic leukaemia (AML), but not with acute lymphoblastic leukaemia of B (ALL-B) or T (ALL-T) cell origin in children.
  • Blood samples and clinical information were collected over the period 1996-2000 from 201 children (0-14 years old) with leukaemia (22 AML, 161 ALL-B and 18 ALL-T cases) through a national network of childhood Hematology-Oncology units in Greece and from 201 controls hospitalised for minor pediatric ailments.
  • Adiponectin was inversely associated with AML (OR=0.56; 95% CI, 0.34-0.94), whereas it was not significantly associated with either ALL-B (OR=0.88; 95% CI, 0.71-1.10) or ALL-T (OR=1.08; 95% CI, 0.67-1.72).
  • Biological plausibility and empirical evidence point to the importance of this hormone in the pathogenesis of childhood AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / physiopathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology
  • [MeSH-minor] Adiponectin / analysis. Adiponectin / biosynthesis. Adolescent. Apoptosis. Body Height. Body Weight. Case-Control Studies. Cell Proliferation. Child. Child, Preschool. Female. Gene Expression Profiling. Greece. Humans. Infant. Infant, Newborn. Leukemia, B-Cell. Leukemia, T-Cell. Male. Odds Ratio

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2004 Nov;127(3):243-63 [15491284.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1160-3 [15001602.001]
  • [Cites] BMJ. 1993 Sep 25;307(6907):774 [8219951.001]
  • [Cites] Nature. 1996 Jul 25;382(6589):352-3 [8684463.001]
  • [Cites] Cancer Causes Control. 1996 Sep;7(5):553-9 [8877054.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83 [10092513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5728-33 [10318952.001]
  • [Cites] Clin Lab Sci. 2004 Fall;17(4):235-45 [15559730.001]
  • [Cites] Eur J Endocrinol. 2004 Dec;151(6):741-6 [15588241.001]
  • [Cites] Am J Epidemiol. 2005 Jan 1;161(1):27-32 [15615910.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1154-7 [16077074.001]
  • [Cites] Circulation. 1999 Dec 21-28;100(25):2473-6 [10604883.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1723-32 [10961870.001]
  • [Cites] Cancer Causes Control. 2000 Sep;11(8):765-71 [11065014.001]
  • [Cites] Circulation. 2001 Feb 27;103(8):1057-63 [11222466.001]
  • [Cites] Diabetes. 2002 Jun;51(6):1884-8 [12031977.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Dec;87(12):5662-7 [12466369.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Mar;88(3):993-7 [12629074.001]
  • [Cites] Diabetologia. 2003 Apr;46(4):459-69 [12687327.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4823-31 [14557461.001]
  • [Cites] Am J Epidemiol. 2003 Oct 15;158(8):724-35 [14561661.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5699-704 [14654554.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2476-81 [14983034.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1102-7 [15001594.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 20;96(20):1549-56 [15494605.001]
  • (PMID = 16404369.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ADIPOQ protein, human; 0 / Adiponectin
  • [Other-IDs] NLM/ PMC2361080
  •  go-up   go-down


93. Rodriguez V, Anderson PM, Litzow MR, Erlandson L, Trotz BA, Arndt CA, Khan SP, Wiseman GA: Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia. Leuk Lymphoma; 2006 Aug;47(8):1583-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia.
  • In four patients, aged 15 - 20 years, with high-risk acute myeloid leukemia (AML), high-dose samarium 153-labelled ethylenediaminetetramethylenephosphonate (153Sm-EDTMP) was used for targeted marrow irradiation before preparative chemotherapy conditioning regimens and allogeneic (three patients) or autologous (one patient) hematopoietic stem cell transplantation.
  • Complete cytogenetic and morphologic remission of AML was evident on follow-up marrow aspirate and biopsy specimens from all patients.
  • Thus, in adolescents and adults, 153Sm-EDTMP may provide a relatively simple and effective means for using irradiation to eliminate AML within the marrow.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / radiotherapy. Radioisotopes / therapeutic use. Samarium / therapeutic use

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Samarium, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966270.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / Organophosphorus Compounds; 0 / Radioisotopes; 122575-21-7 / samarium ethylenediaminetetramethylenephosphonate; 42OD65L39F / Samarium
  •  go-up   go-down


94. Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ: Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics; 2006 Apr;117(4):e711-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IA was defined as aspergillosis that occurred in a child with malignancy (solid tumor, leukemia, or lymphoma), hematologic/immunologic deficiency, or transplant (bone marrow or solid organ).
  • RESULTS: During 2000, there were an estimated 666 pediatric cases of IA among 152,231 immunocompromised children, yielding an annual incidence of 437/100,000 (0.4%) among hospitalized immunocompromised children.
  • The highest incidence of IA was seen in children who had undergone allogeneic bone marrow transplantation (4.5%) and those with acute myelogenous leukemia (4%).
  • Pediatric patients with IA had a significantly longer median length of hospital stay (16 days) than immunocompromised children without IA (3 days).
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Costs and Cost Analysis. Female. Humans. Incidence. Male. United States / epidemiology

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533892.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / K23 AI0629753-01; United States / AHRQ HHS / HS / U18-HS10399
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


95. Lin CH, Hung GY, Chang CY, Chien JC: Subdural hemorrhage in a child with acute promyelocytic leukemia presenting as subtle headache. J Chin Med Assoc; 2005 Sep;68(9):437-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subdural hemorrhage in a child with acute promyelocytic leukemia presenting as subtle headache.
  • Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) and is rare in children (< 10% of childhood AML).
  • We report a 12-year-old child with APL who suffered a subdural hemorrhage and initially presented with a subtle headache mistaken as the side effect of all-trans-retinoic acid (ATRA).
  • Blood component therapy and a pediatric dosage of ATRA (25 mg/m2/day) combined with idarubicin as induction chemotherapy were administered in the first week, but the bleeding diathesis persisted and DIC profiles showed no improvement.
  • This case suggests that the ATRA dosage for pediatric APL patients must be modified according to clinical condition.
  • [MeSH-major] Headache / etiology. Hematoma, Subdural / etiology. Leukemia, Promyelocytic, Acute / complications
  • [MeSH-minor] Child. Disseminated Intravascular Coagulation / complications. Humans. Male. Partial Thromboplastin Time. Prothrombin Time. Tretinoin / adverse effects

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Headache.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16187602.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 5688UTC01R / Tretinoin
  •  go-up   go-down


96. Liang DC, Shih LY, Huang CF, Hung IJ, Yang CP, Liu HC, Jaing TH, Wang LY, Chang WH: CEBPalpha mutations in childhood acute myeloid leukemia. Leukemia; 2005 Mar;19(3):410-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEBPalpha mutations in childhood acute myeloid leukemia.
  • CEBPalpha: mutations have been described in adult acute myeloid leukemia (AML) and conferred a favorable prognosis.
  • We investigated 117 children with de novo AML using DNA PCR assay followed by sequencing for each PCR product.
  • Our results showed that CEBPalpha mutations occurred in 6% of childhood AML and most exhibited combined mutations in both N-terminal part and bZIP domain.
  • [MeSH-major] CCAAT-Enhancer-Binding Protein-alpha / genetics. Leukemia, Myeloid, Acute / genetics. Mutation
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Clone Cells. DNA Mutational Analysis / methods. Gene Frequency. Humans. Infant. Infant, Newborn. Polymerase Chain Reaction / methods


97. Abdel Rahman H, Farrag SA, El-Attar IA: AML1/ETO Fusion Gene in de novo Pediatric Acute Myeloid Leukemia: Clinical Significance and Prognostic Implications. J Egypt Natl Canc Inst; 2007 Mar;19(1):39-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AML1/ETO Fusion Gene in de novo Pediatric Acute Myeloid Leukemia: Clinical Significance and Prognostic Implications.
  • The characterization of leukemia-associated chromosome translocations has contributed relevant insights into our understanding of leukemia pathogenesis and has provided new specific tumor markers essential in prognostic assessment and minimal residual disease studies.
  • The aim of this work is to study the frequency of AML1/ETO fusion gene in a series of Egyptian childhood AML cases.
  • The clinical significance and prognostic implications of this aberration, including CR rate, duration of first CR, extramedullary leukemia (EML), and survival are investigated as well.
  • Peripheral blood and/or bone marrow mononuclear cells were available for analysis from 78 children, all newly diagnosed with AML.
  • Patients with de novo AML were treated by 2 courses of induction chemotherapy, followed by 4 courses of consolidation treatment if the patient achieved complete remission (CR).
  • Lymph nodes were enlarged in 8/15 cases (53.34%), hepatomegly was observed in 4/15 cases (26.67%), splenomegaly in 8/15 cases (53.34%), purpura in 6/15 cases (40%), while pallor was observed in all fifteen cases.Extramedullary leukemia occurred in 4/15 cases (26.67%).
  • In conclusion, we report a frequency of 19.2% of AML1/ETO fusion gene in our newly diagnosed pediatric AML cases.
  • Key Words: Pediatric acute myeloid leukemia , AML1/ETO fusion gene , RT-PCR , Clinical outcome , Prognostic significance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18839034.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


98. Meyer S, Barber LM, White DJ, Will AM, Birch JM, Kohler JA, Ersfeld K, Blom E, Joenje H, Eden TO, Malcolm Taylor G: Spectrum and significance of variants and mutations in the Fanconi anaemia group G gene in children with sporadic acute myeloid leukaemia. Br J Haematol; 2006 May;133(3):284-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum and significance of variants and mutations in the Fanconi anaemia group G gene in children with sporadic acute myeloid leukaemia.
  • Childhood acute myeloid leukaemia (AML) is uncommon.
  • Children with Fanconi anaemia (FA), however, have a very high risk of developing AML.
  • To address to what extent FANCG variants contribute to sporadic childhood AML, we determined the spectrum of FANCG sequence variants in 107 children diagnosed with sporadic AML, using polymerase chain reaction (PCR), fluorescent single-strand conformational polymorphism (SSCP) and sequencing methodologies.
  • R513Q, which affects a semi-conserved amino acid, was carried in two additional children with AML.
  • Although not significant, the frequency of R513Q was higher in children with AML than unselected cord bloods.
  • While FANCG mutation carrier status does not predispose to sporadic AML, the identification of unrecognised FA patients implies that FA presenting with primary AML in childhood is more common than suspected.
  • [MeSH-major] Fanconi Anemia / complications. Fanconi Anemia Complementation Group G Protein / genetics. Leukemia, Myeloid / genetics. Mutation
  • [MeSH-minor] Acute Disease. Adolescent. Amino Acid Sequence. Animals. Child. Child, Preschool. DNA, Neoplasm / genetics. Female. Humans. Infant. Male. Molecular Sequence Data. Polymerase Chain Reaction / methods. Polymorphism, Single-Stranded Conformational. Sequence Alignment

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16643430.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Fanconi Anemia Complementation Group G Protein
  •  go-up   go-down


99. Levine JE, Barrett AJ, Zhang MJ, Arora M, Pulsipher MA, Bunin N, Fort J, Loberiza F, Porter D, Giralt S, Drobyski W, Wang D, Pavletic S, Ringden O, Horowitz MM, Collins R Jr: Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplant; 2008 Aug;42(3):201-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population.
  • [MeSH-minor] Acute Disease. Child. Combined Modality Therapy. Disease-Free Survival. Female. Graft vs Host Disease / epidemiology. Graft vs Tumor Effect. Humans. Leukemia / surgery. Leukemia / therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Male. Recurrence. Tissue Donors. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18490913.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


100. Irshad FA, Gordon RA: Bartonella henselae neuroretinitis in a 15-year-old girl with chronic myelogenous leukemia. J AAPOS; 2009 Dec;13(6):602-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bartonella henselae neuroretinitis in a 15-year-old girl with chronic myelogenous leukemia.
  • A 15-year-old girl being treated with imatinib for chronic myelogenous leukemia (CML) presented with acute vision loss in her right eye accompanied by swelling of the right side of her neck.

  • MedlinePlus Health Information. consumer health - Cat Scratch Disease.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20006827.001).
  • [ISSN] 1528-3933
  • [Journal-full-title] Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
  • [ISO-abbreviation] J AAPOS
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antibodies, Bacterial; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Immunoglobulin G; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; N12000U13O / Doxycycline
  •  go-up   go-down






Advertisement